Modification of the Clinical Global Impressions (CGI) so the CGI-BP

Psychiatry Research 73, 159-171

DOI: 10.1016/s0165-1781(97)00123-6

Citation Report

#	Article	IF	CITATIONS
1	Olanzapine in treatment-resistant bipolar disorder. Journal of Affective Disorders, 1998, 49, 119-122.	2.0	95
2	Statistical approaches to trial durations in episodic affective illness. Psychiatry Research, 1998, 78, 71-87.	1.7	18
4	The Use of Quetiapine for Treatment-Resistant Bipolar Disorder: A Case Series. Annals of Clinical Psychiatry, 1999, 11, 137-140.	0.6	63
5	Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disorders, 1999, 1, 42-53.	1.1	135
6	Gabapentin in the acute treatment of refractory bipolar disorder. Bipolar Disorders, 1999, 1, 61-65.	1.1	57
7	Lamotrigine for the treatment of bipolar disorder: a clinical case series. Journal of Affective Disorders, 1999, 53, 95-98.	2.0	65
8	Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression. Biological Psychiatry, 1999, 45, 285-289.	0.7	28
9	Acute and continuation pharmacological treatment of children and adolescents with bipolar disorders; a summary of two previous studies. Acta Neuropsychiatrica, 2000, 12, 145-149.	1.0	5
10	Response to placebo among bipolar I disorder patients experiencing their first manic episode. Bipolar Disorders, 2000, 2, 332-335.	1.1	7
11	Efficacy of Olanzapine in Acute Bipolar Mania <subtitle>A Double-blind, Placebo-Controlled Study</subtitle> . Archives of General Psychiatry, 2000, 57, 841.	13.8	506
12	Open-label adjunctive topiramate in the treatment of bipolar disorders. Biological Psychiatry, 2000, 47, 1025-1033.	0.7	203
13	Effect Size of Lithium, Divalproex Sodium, and Carbamazepine in Children and Adolescents With Bipolar Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2000, 39, 713-720.	0.3	332
14	Adjunctive gabapentin treatment of bipolar disorder. European Psychiatry, 2000, 15, 433-437.	0.1	38
15	Methodological issues in developing new acute treatments for patients with bipolar illness. Biological Psychiatry, 2000, 48, 615-624.	0.7	23
16	Pharmacologic agents for the treatment of acute bipolar mania. Biological Psychiatry, 2000, 48, 539-557.	0.7	142
17	Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. European Psychiatry, 2001, 16, 186-190.	0.1	78
18	ECNP Consensus Meeting March 2000 Nice. European Neuropsychopharmacology, 2001, 11, 79-88.	0.3	33
19	Olanzapine. CNS Drugs, 2001, 15, 871-904.	2.7	56

#	Article	IF	CITATIONS
20	Olanzapine as Long-Term Adjunctive Therapy in Treatment-Resistant Bipolar Disorder. Journal of Clinical Psychopharmacology, 2001, 21, 469-473.	0.7	59
21	Study of Health in Pomerania (SHIP): A health examination survey in an east German region: Objectives and design. International Journal of Public Health, 2001, 46, 186-194.	2.7	477
22	Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disorders, 2001, 3, 259-265.	1.1	97
23	Subjective response to and tolerability of long-term supraphysiological doses of levothyroxine in refractory mood disorders. Journal of Affective Disorders, 2001, 64, 35-42.	2.0	50
24	Gabapentin treatment of the non-refractory bipolar spectrum: an open case series. Journal of Affective Disorders, 2001, 65, 167-171.	2.0	27
25	Long-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex vs. lithium in the setting of minimal antidepressant use. Journal of Affective Disorders, 2001, 65, 281-287.	2.0	31
26	The Stanley Foundation Bipolar Treatment Outcome Network. Journal of Affective Disorders, 2001, 67, 33-44.	2.0	162
27	Decreased Anterior Cingulate Myo-inositol/Creatine Spectroscopy Resonance with Lithium Treatment in Children with Bipolar Disorder. Neuropsychopharmacology, 2001, 24, 359-369.	2.8	227
28	Rating and quantification of manic syndromes. Acta Psychiatrica Scandinavica, 2001, 104, 2-33.	2.2	3
29	The Stanley Foundation Bipolar Network. British Journal of Psychiatry, 2001, 178, s169-s176.	1.7	96
30	The Stanley Foundation Bipolar Network. British Journal of Psychiatry, 2001, 178, s177-s183.	1.7	39
31	Topiramate Plus Risperidone for Controlling Weight Gain and Symptoms in Preschool Mania. Journal of Child and Adolescent Psychopharmacology, 2002, 12, 271-273.	0.7	41
32	Adjunctive Topiramate Treatment for Pediatric Bipolar Disorder: A Retrospective Chart Review. Journal of Child and Adolescent Psychopharmacology, 2002, 12, 323-330.	0.7	78
33	The Stanley Foundation Bipolar Network: Results of the Naturalistic Follow-Up Study after 2.5 Years of Follow-Up in the German Centres. Neuropsychobiology, 2002, 46, 2-9.	0.9	56
34	Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. International Clinical Psychopharmacology, 2002, 17, 227-237.	0.9	55
35	Review of the Use of Topiramate for Treatment of Bipolar Disorders. Journal of Clinical Psychopharmacology, 2002, 22, 599-609.	0.7	205
36	Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biological Psychiatry, 2002, 51, 253-260.	0.7	97
37	The Life Functioning Questionnaire (LFQ): a brief, gender-neutral scale assessing functional outcome. Psychiatry Research, 2002, 112, 161-182.	1.7	60

#	Article	IF	Citations
38	Electroconvulsive therapy in treatment-resistant mania: case reports. Revista Do Hospital Das Clinicas, 2002, 57, 31-38.	0.5	2
39	An open case series on the utility of tiagabine as an augmentation in refractory bipolar outpatients. Journal of Affective Disorders, 2002, 71, 259-263.	2.0	32
40	Presentations of depression in bipolar illness. Clinical Neuroscience Research, 2002, 2, 142-157.	0.8	12
41	Acute and prophylactic effects of anticonvulsants in bipolar depression. Clinical Neuroscience Research, 2002, 2, 228-251.	0.8	19
42	Supraphysiological Doses of L-Thyroxine in the Maintenance Treatment of Prophylaxis-Resistant Affective Disorders. Neuropsychopharmacology, 2002, 27, 620-8.	2.8	55
43	Utility of the daily prospective National Institute of Mental Health Life-Chart Method (NIMH-LCM-p) ratings in clinical trials of bipolar disorder. Depression and Anxiety, 2002, 15, 1-9.	2.0	48
44	A clinical monitoring form for mood disorders. Bipolar Disorders, 2002, 4, 323-327.	1.1	131
45	Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disorders, 2002, 4, 283-289.	1.1	62
46	Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disorders, 2002, 4, 335-340.	1.1	74
47	Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. Bipolar Disorders, 2002, 4, 412-417.	1.1	49
48	Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. Journal of Affective Disorders, 2003, 73, 155-161.	2.0	64
49	Unique design issues in clinical trials of patients with bipolar affective disorder. Journal of Psychiatric Research, 2003, 37, 61-73.	1.5	40
50	Assessment of treatment response in mania: commentary and new findings. Bipolar Disorders, 2003, 5, 79-84.	1.1	11
51	An overview of recent findings of the Stanley Foundation Bipolar Network (Part I). Bipolar Disorders, 2003, 5, 310-319.	1.1	128
52	Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania. Bipolar Disorders, 2003, 5, 1-5.	1.1	74
53	The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatrica Scandinavica, 2003, 107, 16-23.	2.2	508
54	The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatrica Scandinavica, 2003, 107, 222-232.	2.2	98
55	A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network. Bipolar Disorders, 2003, 5, 396-406.	1.1	128

#	ARTICLE	IF	CITATIONS
56	Low CSF somatostatin associated with response to nimodipine in patents with affective illness. Biological Psychiatry, 2003, 53, 180-183.	0.7	18
57	The InterSePT scale for suicidal thinking reliability and validity. Schizophrenia Research, 2003, 63, 161-170.	1.1	94
58	Adjunctive quetiapine in bipolar patients partially responsive to lithium or valproate. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 863-866.	2.5	32
59	Clinician ratings vs. global ratings of symptom severity: a comparison of symptom measures in the bipolar disorder module, phase II, Texas Medication Algorithm Project. Psychiatry Research, 2003, 117, 167-175.	1.7	6
60	A 12-Week, Double-blind Comparison of Olanzapine vs Haloperidol in the Treatment of Acute Mania. Archives of General Psychiatry, 2003, 60, 1218.	13.8	198
61	Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression. Archives of General Psychiatry, 2003, 60, 1079.	13.8	797
62	Impact of Antidepressant Discontinuation After Acute Bipolar Depression Remission on Rates of Depressive Relapse at 1-Year Follow-Up. American Journal of Psychiatry, 2003, 160, 1252-1262.	4.0	265
63	A Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Aripiprazole in Patients With Acute Bipolar Mania. American Journal of Psychiatry, 2003, 160, 1651-1658.	4.0	419
64	A Preliminary Study of the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children Mania Rating Scale for Children and Adolescents. Journal of Child and Adolescent Psychopharmacology, 2003, 13, 463-470.	0.7	267
65	Olanzapine Versus Divalproex Sodium for the Treatment of Acute Mania and Maintenance of Remission: A 47-Week Study. American Journal of Psychiatry, 2003, 160, 1263-1271.	4.0	294
66	Valproate for acute mood episodes in bipolar disorder. The Cochrane Library, 2003, , CD004052.	1.5	70
67	Adjunctive topiramate in bipolar II disorder. World Journal of Biological Psychiatry, 2003, 4, 172-176.	1.3	18
68	Olanzapine Versus Placebo in Acute Mania. Journal of Clinical Psychopharmacology, 2003, 23, 370-376.	0.7	58
69	Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Current Medical Research and Opinion, 2004, 20, 827-835.	0.9	69
70	Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disorders, 2004, 6, 213-223.	1.1	236
71	The prevalence of the metabolic syndrome in patients with schizoaffective disorder - bipolar subtype. Bipolar Disorders, 2004, 6, 314-318.	1.1	115
72	Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disorders, 2004, 6, 416-420.	1.1	64
73	The prevalence and clinical correlates of anger attacks during depressive episodes in bipolar disorder. Journal of Affective Disorders, 2004, 79, 291-295.	2.0	82

#	Article	IF	Citations
74	Sequence analysis of ADARB1 gene in patients with familial bipolar disorder. Journal of Affective Disorders, 2004, 81, 79-85.	2.0	8
75	Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. Journal of Affective Disorders, 2004, 82, S103-S111.	2.0	118
76	A Pharmacotherapy Algorithm for Stabilization and Maintenance of Pediatric Bipolar Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2004, 43, 859-867.	0.3	59
77	A high prevalence of organ-specific autoimmunity in patients with bipolar disorder. Biological Psychiatry, 2004, 56, 476-482.	0.7	96
78	Child- and Family-Focused Cognitive-Behavioral Therapy for Pediatric Bipolar Disorder: Development and Preliminary Results. Journal of the American Academy of Child and Adolescent Psychiatry, 2004, 43, 528-537.	0.3	227
79	How real are patients in placebo-controlled studies of acute manic episode?. European Neuropsychopharmacology, 2004, 14, 319-323.	0.3	16
80	Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: Secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clinical Therapeutics, 2004, 26, 125-134.	1.1	54
81	Aripiprazole for Acute Bipolar Mania. American Journal of Psychiatry, 2004, 161, 1926-a-1927.	4.0	3
82	Open-Label Adjunctive Topiramate in the Treatment of Unstable Bipolar Disorder. Canadian Journal of Psychiatry, 2005, 50, 415-422.	0.9	29
83	Efficacy of Electroconvulsive Therapy in Treatment-Resistant Bipolar Disorder. Journal of ECT, 2005, 21, 31-34.	0.3	30
84	Aripiprazole: Initial Clinical Experience with 142 Hospitalized Psychiatric Patients. Journal of Psychiatric Practice, 2005, 11, 241-247.	0.3	34
85	Carbamazepine extended-release capsules for the treatment of bipolar I disorder. Therapy: Open Access in Clinical Medicine, 2005, 2, 533-544.	0.2	1
86	Recovery and functional outcomes following olanzapine treatment for bipolar I mania. Bipolar Disorders, 2005, 7, 68-76.	1.1	43
87	Divalproex sodium for pediatric mixed mania: a 6-month prospective trial. Bipolar Disorders, 2005, 7, 266-273.	1.1	67
88	Zotepine loading in acute and severely manic patients: a pilot study. Bipolar Disorders, 2005, 7, 471-476.	1.1	43
89	Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression. Molecular Psychiatry, 2005, 10, 456-469.	4.1	144
90	Lamotrigine for the treatment of bipolar spectrum disorder: a chart review. Journal of Affective Disorders, 2005, 86, 69-73.	2.0	10
91	Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: Post hoc analyses of 47-week data. Journal of Affective Disorders, 2005, 89, 69-77.	2.0	41

#	Article	IF	CITATIONS
93	Olanzapine co-therapy in bipolar disorder. British Journal of Psychiatry, 2005, 187, 486-487.	1.7	0
94	Work-Related Subjective Experiences Among Community Residents with Schizophrenia or Schizoaffective Disorder. Australian and New Zealand Journal of Psychiatry, 2005, 39, 288-299.	1.3	13
95	Comparison of Olanzapine and Risperidone in 367 First-Episode Patients with Non-Affective or Affective Psychosis: Results of an Open Retrospective Medical Record Study. Pharmacopsychiatry, 2005, 38, 206-213.	1.7	35
96	Carbamazepine extended-release capsules: a new treatment option for bipolar I disorder. Expert Review of Neurotherapeutics, 2005, 5, 587-595.	1.4	4
97	Adjunctive Topiramate in Hospitalized Children and Adolescents with Bipolar Disorders. Journal of Child and Adolescent Psychopharmacology, 2005, 15, 931-937.	0.7	24
98	Combination quetiapine therapy in the long-term treatment of patients with bipolar I disorder. Clinical Practice and Epidemiology in Mental Health, 2005, 1, 7.	0.6	10
99	Effectiveness of aripiprazole v. Haloperidol in acute bipolar mania. British Journal of Psychiatry, 2005, 187, 235-242.	1.7	166
100	Mixed Hypomania in 908 Patients With Bipolar Disorder Evaluated Prospectively in the Stanley Foundation Bipolar Treatment Network. Archives of General Psychiatry, 2005, 62, 1089.	13.8	175
101	Quetiapine or haloperidol as monotherapy for bipolar maniaâ€"a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. European Neuropsychopharmacology, 2005, 15, 573-585.	0.3	195
102	Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Biological Psychiatry, 2005, 57, 220-228.	0.7	80
103	Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. Journal of Psychopharmacology, 2006, 20, 536-546.	2.0	233
104	Extended-Release Carbamazepine Capsules as Monotherapy in Bipolar Disorder. CNS Drugs, 2006, 20, 219-231.	2.7	70
105	Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. British Journal of Psychiatry, 2006, 189, 124-131.	1.7	310
106	Monocyte-Derived Dendritic Cells in Bipolar Disorder. Biological Psychiatry, 2006, 59, 317-326.	0.7	36
107	Double-Blind, Randomized, Placebo-Controlled Trials of Ethyl-Eicosapentanoate in the Treatment of Bipolar Depression and Rapid Cycling Bipolar Disorder. Biological Psychiatry, 2006, 60, 1020-1022.	0.7	219
108	Lithium Treatment Effects on Myo-Inositol in Adolescents with Bipolar Depression. Biological Psychiatry, 2006, 60, 998-1004.	0.7	51
109	Open-Label Lithium for the Treatment of Adolescents With Bipolar Depression. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 289-297.	0.3	102
111	Second-generation antidepressant discontinuation and depressive relapse in adult patients with bipolar depression: Results of a retrospective database analysis. Clinical Therapeutics, 2006, 28, 979-989.	1.1	9

#	Article	IF	CITATIONS
112	Tiagabine in the maintenance treatment of bipolar disorders. , 2006, , CD005173.		4
113	Long-Term Lamotrigine Plus Lithium for Bipolar Disorder: One Year Outcome. Journal of Psychiatric Practice, 2006, 12, 300-305.	0.3	13
114	An Exploratory Open Trial on Safety and Efficacy of the Anticonvulsant Retigabine in Acute Manic Patients. Journal of Clinical Psychopharmacology, 2006, 26, 534-536.	0.7	17
115	Prediction of Functional Outcome 18 Months After a First Psychotic Episode. Archives of General Psychiatry, 2006, 63, 969.	13.8	56
116	Zotepine loading in acute and severely manic patients: a pilot study. Annals of General Psychiatry, $2006, 5, 1$ .	1.2	0
117	A relative resistance of T cells to dexamethasone in bipolar disorder. Bipolar Disorders, 2006, 8, 740-750.	1.1	49
118	Evidence for three distinct classes of 'typical', 'psychotic' and 'dual' mania: results from the EMBLEM study. Acta Psychiatrica Scandinavica, 2006, 113, 112-120.	2.2	75
119	Influence of the catechol-O-methyltransferase Val108/158Met polymorphism on the plasma concentration of catecholamine metabolites and on clinical features in type I bipolar disorderâ€"A preliminary report. Journal of Affective Disorders, 2006, 92, 277-281.	2.0	21
120	Clinical relevance of depressive symptom improvement in bipolar I depressed patients. Journal of Affective Disorders, 2006, 92, 261-266.	2.0	27
121	Outcomes and Length of Treatment With Carbamazepine Extended-Release Capsules in Bipolar Disorder. Annals of Clinical Psychiatry, 2006, 18, 15-18.	0.6	O
122	Safety of Carbamazepine Extended-Release Capsules in Bipolar Disorder Polypharmacy. Annals of Clinical Psychiatry, 2006, 18, 19-22.	0.6	6
123	Carbamazepine Extended-Release Capsules Use in Bipolar Disorder: Efficacy and Safety in Adult Patients. Annals of Clinical Psychiatry, 2006, 18, 9-14.	0.6	1
124	Lower Switch Rate in Depressed Patients With Bipolar II Than Bipolar I Disorder Treated Adjunctively With Second-Generation Antidepressants. American Journal of Psychiatry, 2006, 163, 313-315.	4.0	140
125	An open label follow-up study on amisulpride in the add-on treatment of bipolar I patients. Clinical Practice and Epidemiology in Mental Health, 2006, 2, 19.	0.6	12
126	Preliminary Study of Relationships Among Measures of Depressive Symptoms in Adolescents with Bipolar Disorder. Journal of Child and Adolescent Psychopharmacology, 2006, 16, 327-335.	0.7	6
127	AOne-Year Open-Label Trial of Risperidone Augmentation in Lithium Nonresponder Youth with Preschool-Onset Bipolar Disorder. Journal of Child and Adolescent Psychopharmacology, 2006, 16, 336-350.	0.7	64
128	A Double-Blind, Randomized, Placebo-Controlled Trial of Oxcarbazepine in the Treatment of Bipolar Disorder in Children and Adolescents. American Journal of Psychiatry, 2006, 163, 1179-1186.	4.0	177
129	Comparison of Two Anticonvulsants in a Randomized, Single-Blind Treatment of Hypomanic Symptoms in Patients with Bipolar Disorder. Australian and New Zealand Journal of Psychiatry, 2007, 41, 397-402.	1.3	13

#	Article	IF	Citations
130	Work-Related Subjective Experiences, Work-Related Self-Efficacy, and Career Learning Among People with Psychiatric Disabilities. American Journal of Psychiatric Rehabilitation, 2007, 10, 275-300.	0.7	30
131	Risperidone monotherapy in manic inpatients: An open label, multicentre trial. World Journal of Biological Psychiatry, 2007, 8, 256-261.	1.3	7
132	Olanzapine Versus Placebo in the Treatment of Adolescents With Bipolar Mania. American Journal of Psychiatry, 2007, 164, 1547-1556.	4.0	238
133	Lower Switch Rate in Depressed Patients With Bipolar II Than Bipolar I Disorder Treated Adjunctively With Second-Generation Antidepressants. Focus (American Psychiatric Publishing), 2007, 5, 107-110.	0.4	2
134	Quetiapine as add-on treatment for bipolar I disorder: efficacy in preventing relapse of depressive episodes. Clinical Practice and Epidemiology in Mental Health, 2007, 3, 17.	0.6	4
135	A Placebo-Controlled Evaluation of Adjunctive Modafinil in the Treatment of Bipolar Depression. American Journal of Psychiatry, 2007, 164, 1242-1249.	4.0	224
136	Symptom rating scales and outcome in schizophrenia. British Journal of Psychiatry, 2007, 191, s7-s14.	1.7	114
137	Outcomes for Latin American Versus White Patients Suffering From Acute Mania in a Randomized, Double-Blind Trial Comparing Olanzapine and Haloperidol. Journal of Clinical Psychopharmacology, 2007, 27, 126-134.	0.7	18
138	Acute Pancreatitis and Diabetic Ketoacidosis in a Schizophrenic Patient Taking Olanzapine. Journal of Clinical Psychopharmacology, 2007, 27, 397-400.	0.7	21
139	Treatment of Antipsychotic-Associated Hyperglycemia With Pioglitazone. Journal of Clinical Psychopharmacology, 2007, 27, 403-404.	0.7	11
140	Exacerbation of Myoclonus by Memantine in a Patient With Alzheimer Disease. Journal of Clinical Psychopharmacology, 2007, 27, 407-408.	0.7	14
141	Suicidality Scores During Double-Blind Fluoxetine and Desipramine Treatment in Mexican Americans. Journal of Clinical Psychopharmacology, 2007, 27, 99-102.	0.7	4
142	Attitude of Patients With Mood Disorder Toward Clinical Trials in Japan. Journal of Clinical Psychopharmacology, 2007, 27, 93-94.	0.7	0
143	Fluvoxamine in the Treatment of Late-Life Depression: How Much We Know Coming From Randomized Controlled Trials. Journal of Clinical Psychopharmacology, 2007, 27, 98-99.	0.7	2
144	Depressive Symptoms in Urticaria Patients Treated With First- or Second-Generation Histamine 1 Receptor Antagonists. Journal of Clinical Psychopharmacology, 2007, 27, 404-406.	0.7	3
145	Severe Hypoglycemia Following Venlafaxine Intoxication. Journal of Clinical Psychopharmacology, 2007, 27, 414-415.	0.7	17
146	Use of Alcohol During the Treatment of Alcohol Dependence With $\hat{I}^3$ -Hydroxybutyric Acid. Journal of Clinical Psychopharmacology, 2007, 27, 418.	0.7	5
147	Combined Overdose of Atomoxetine and Methylphenidate in a Cytochrome P450 2D6 Poor Metabolizer. Journal of Clinical Psychopharmacology, 2007, 27, 110-111.	0.7	7

#	ARTICLE	IF	Citations
148	Quetiapine in a Case With Parkinson Disease and Pathological Gambling. Journal of Clinical Psychopharmacology, 2007, 27, 106-107.	0.7	37
149	Duloxetine-Induced Excessive Disturbing and Disabling Yawning. Journal of Clinical Psychopharmacology, 2007, 27, 106-107.	0.7	14
150	Mood-Elevating Effects of Opioid Analgesics in Patients With Bipolar Disorder. Journal of Neuropsychiatry and Clinical Neurosciences, 2007, 19, 449-452.	0.9	18
151	Duloxetine and Hyponatremia. Journal of Clinical Psychopharmacology, 2007, 27, 101-104.	0.7	26
152	Duloxetine-Induced Ultrarapid Cycling in an Adolescent With Bipolar Depression. Journal of Clinical Psychopharmacology, 2007, 27, 115-116.	0.7	6
153	Venlafaxine Discontinuation Syndrome and Suicidal Ideation. Journal of Clinical Psychopharmacology, 2007, 27, 94-95.	0.7	9
154	Sex Differences in Antidepressant Response in a Canadian Primary-Care Sample. Journal of Clinical Psychopharmacology, 2007, 27, 95-98.	0.7	4
155	Association of Acute Symptoms and Compliance Attitude in Noncompliant Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2007, 27, 392-394.	0.7	15
156	Cervical Dystonia Due to Interaction of Valproic Acid and Quetiapine. Journal of Clinical Psychopharmacology, 2007, 27, 396-397.	0.7	14
157	Discontinuation of Risperidone, Olanzapine, and Haloperidol in First-Episode Psychosis. Journal of Clinical Psychopharmacology, 2007, 27, 400-401.	0.7	2
158	An Open-Label Trial of Discontinuing Benzodiazepines in Patients With Chronic Schizophrenia. Journal of Clinical Psychopharmacology, 2007, 27, 401-403.	0.7	6
159	Lithium Toxicity Presenting as Catatonia in an Adolescent Girl. Journal of Clinical Psychopharmacology, 2007, 27, 410-412.	0.7	13
160	Disulfiram in Context. Journal of Clinical Psychopharmacology, 2007, 27, 415-417.	0.7	7
161	Rating Rater Improvement. Journal of Clinical Psychopharmacology, 2007, 27, 418-420.	0.7	18
162	Why Do Clinical Trials Fail?. Journal of Clinical Psychopharmacology, 2007, 27, 420-421.	0.7	6
163	Inhibition of Selective Noradrenergic Reuptake as Treatment of Pathological Laughter. Journal of Clinical Psychopharmacology, 2007, 27, 108-110.	0.7	14
164	Rating the Raters-Who is the Research Subject?. Journal of Clinical Psychopharmacology, 2007, 27, 116.	0.7	1
165	Reply to Comments by Dr Rico-Villademoros. Journal of Clinical Psychopharmacology, 2007, 27, 99.	0.7	2

#	ARTICLE	IF	CITATIONS
166	Reversible Delayed Onset Olanzapine-Associated Leukopenia and Neutropenia in a Clozapine-Naive Patient on Concomitant Depot Antipsychotic. Journal of Clinical Psychopharmacology, 2007, 27, 394-395.	0.7	5
167	Transient Hyperglycemia and Decreased Glucose Tolerance During Antipsychotic Monotherapy With Amisulpride. Journal of Clinical Psychopharmacology, 2007, 27, 92-93.	0.7	2
168	Clozapine-Associated Restless Legs Syndrome. Journal of Clinical Psychopharmacology, 2007, 27, 89-90.	0.7	35
169	Reply to Comments by Dr. Balon. Journal of Clinical Psychopharmacology, 2007, 27, 116-117.	0.7	O
170	Olanzapine-Induced Chylomicronemia Presenting as Acute Pancreatitis. Journal of Clinical Psychopharmacology, 2007, 27, 395-396.	0.7	15
171	Treatment Adherence in Individuals With Rapid Cycling Bipolar Disorder. Journal of Clinical Psychopharmacology, 2007, 27, 412-414.	0.7	21
172	Effect of Open-Label Lamotrigine as Monotherapy and Adjunctive Therapy on the Self-Assessed Cognitive Function Scores of Patients With Bipolar I Disorder. Journal of Clinical Psychopharmacology, 2007, 27, 387-391.	0.7	15
173	The Asp40 ν-Opioid Receptor Allele Does Not Predict Naltrexone Treatment Efficacy in Heavy Drinkers. Journal of Clinical Psychopharmacology, 2007, 27, 112-114.	0.7	20
174	A 2-Year, Open-Label Pilot Study of Adjunctive Chromium in Patients With Treatment-Resistant Rapid-Cycling Bipolar Disorder. Journal of Clinical Psychopharmacology, 2007, 27, 104-106.	0.7	11
175	Levetiracetam for Manic Behavior in Hospitalized Geriatric Patients With Dementia of the Alzheimer's Type. Journal of Clinical Psychopharmacology, 2007, 27, 408-410.	0.7	19
176	Gabapentin-Related Changes in Renal Function. Journal of Clinical Psychopharmacology, 2007, 27, 118-119.	0.7	3
177	Reply to Comments by Mr Martin and Dr Beresford. Journal of Clinical Psychopharmacology, 2007, 27, 417-418.	0.7	1
178	Reply to Comments by Drs Rickels and Robinson. Journal of Clinical Psychopharmacology, 2007, 27, 421.	0.7	1
179	First Case of Sialolithiasis Associated With Atomoxetine. Journal of Clinical Psychopharmacology, 2007, 27, 111-112.	0.7	4
180	A Case-Control Study of Patients With Resistant Schizophrenia After Clozapine Discontinuation. Journal of Clinical Psychopharmacology, 2007, 27, 90-91.	0.7	6
181	Eating disorders and illness burden in patients with bipolar spectrum disorders. Comprehensive Psychiatry, 2007, 48, 516-521.	1.5	28
182	Pharmacotherapeutic strategies for pediatric bipolar disorder. Expert Opinion on Pharmacotherapy, 2007, 8, 1801-1819.	0.9	12
183	Response and Remission in Adolescent Mania. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, 46, 628-635.	0.3	23

#	Article	IF	CITATIONS
184	Maintenance Model of Integrated Psychosocial Treatment in Pediatric Bipolar Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, 46, 205-212.	0.3	76
185	Adaptive Strategies for Treating Childhood Mania. Biological Psychiatry, 2007, 61, 758-764.	0.7	12
186	Schizophrenia: Measurements of Psychopathology. Psychiatric Clinics of North America, 2007, 30, 339-363.	0.7	24
187	An open-label study of quetiapine in anorexia nervosa. Human Psychopharmacology, 2007, 22, 223-230.	0.7	29
188	The management of bipolar mania: a national survey of baseline data from the EMBLEM study in Italy. BMC Psychiatry, 2007, 7, 33.	1.1	13
189	The improved Clinical Global Impression Scale (iCGI): development and validation in depression. BMC Psychiatry, 2007, 7, 7.	1.1	133
190	The Firstâ€Episode Psychosis Outcome Study: premorbid and baseline characteristics of an epidemiological cohort of 661 firstâ€episode psychosis patients. Microbial Biotechnology, 2007, 1, 191-200.	0.9	100
191	Functional impairment in patients with mania: baseline results of the EMBLEM study. Bipolar Disorders, 2007, 9, 45-52.	1.1	116
192	Mood and anxiety spectrum as a means to identify clinically relevant subtypes of bipolar I disorder. Bipolar Disorders, 2007, 9, 462-467.	1.1	23
193	An imbalance in the production of IL- $1\hat{l}^2$ and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disorders, 2007, 9, 743-753.	1.1	128
194	Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psychiatrica Scandinavica, 2007, 115, 360-365.	2.2	51
195	Open-label aripiprazole in the treatment of acute bipolar depression: A prospective pilot trial. Journal of Affective Disorders, 2007, 101, 275-281.	2.0	50
196	The social, psychopathological and consumer context of rate of symptom improvement in acute mania. Social Psychiatry and Psychiatric Epidemiology, 2007, 42, 631-638.	1.6	9
197	Longâ€Chain Omegaâ€3 Polyunsaturated Fatty Acids in the Blood of Children and Adolescents with Juvenile Bipolar Disorder. Lipids, 2008, 43, 1031-1038.	0.7	65
198	Targeted scoring criteria reduce variance in global impressions. Human Psychopharmacology, 2008, 23, 629-633.	0.7	14
199	Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change. Bipolar Disorders, 2008, 10, 566-579.	1.1	40
200	Quetiapine for the treatment of bipolar mania in older adults. Bipolar Disorders, 2008, 10, 662-671.	1.1	55
201	The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use. Journal of Evaluation in Clinical Practice, 2008, 14, 979-983.	0.9	194

#	Article	IF	CITATIONS
202	Weight change in the acute treatment of bipolar I disorder: A naturalistic observational study of psychiatric inpatients. Journal of Affective Disorders, 2008, 105, 45-52.	2.0	38
203	Olanzapine versus lithium in the acute treatment of bipolar mania: A double-blind, randomized, controlled trial. Journal of Affective Disorders, 2008, 105, 101-108.	2.0	62
204	Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study. Journal of Affective Disorders, 2008, 106, 63-72.	2.0	47
205	The empirical redefinition of the psychometric criteria for remission in bipolar disorder. Journal of Affective Disorders, 2008, 106, 153-158.	2.0	78
206	The Bipolar Comprehensive Outcomes Study (BCOS): Baseline findings of an Australian cohort study. Journal of Affective Disorders, 2008, 107, 135-144.	2.0	12
207	A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders, 2008, 111, 334-343.	2.0	84
208	Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). Journal of Affective Disorders, 2008, 109, 251-263.	2.0	221
209	Rapid-cycling bipolar I disorder: Course and treatment outcome of a large sample across Europe. Journal of Psychiatric Research, 2008, 42, 1068-1075.	1.5	56
210	Validation of a Clinical Global Impression Scale for Aggression (CGI-A) in a sample of 558 psychiatric patients. Schizophrenia Research, 2008, 100, 342-348.	1.1	39
211	Is there a role for <i>n</i> -3 long-chain polyunsaturated fatty acids in the regulation of mood and behaviour? A review of the evidence to date from epidemiological studies, clinical studies and intervention trials. Nutrition Research Reviews, 2008, 21, 13-41.	2.1	104
215	Prevalence and correlates of eating disorder co-morbidity in patients with bipolar disorder. Psychiatry Research, 2008, 161, 51-58.	1.7	61
216	Stability and treatment outcome of distinct classes of mania. European Psychiatry, 2008, 23, 360-367.	0.1	18
217	Chronic mania revisited: Factors associated with treatment non-response during prospective follow-up of a large European cohort (EMBLEM). World Journal of Biological Psychiatry, 2008, 9, 313-320.	1.3	22
218	Development and validation of the Affective Self Rating Scale for manic, depressive, and mixed affective states. Nordic Journal of Psychiatry, 2008, 62, 130-135.	0.7	26
219	Protein Kinase C Inhibition in the Treatment of Mania. Archives of General Psychiatry, 2008, 65, 255.	13.8	197
220	Olanzapine plus carbamazepine <i>v.</i> carbamazepine alone in treating manic episodes. British Journal of Psychiatry, 2008, 192, 135-143.	1.7	75
221	A 12-week, open, randomized trial comparing sodium valproate to lithium in patients with bipolar I disorder suffering from a manic episode. International Clinical Psychopharmacology, 2008, 23, 254-262.	0.9	36
222	Treatment of Severe Agitation with Olanzapine in 166 Patients with Schizophrenia, Schizoaffective, or Bipolar I Disorder. Pharmacopsychiatry, 2008, 41, 182-189.	1.7	23

#	Article	IF	Citations
223	Temporal Change in N-Acetyl-Aspartate Concentrations in Adolescents with Bipolar Depression Treated with Lithium. Journal of Child and Adolescent Psychopharmacology, 2008, 18, 132-139.	0.7	70
224	Reply to Comments by Dr Lin "Duloxetine Treatment of Social Anxiety Disorder With Comorbid Major Depression". Journal of Clinical Psychopharmacology, 2008, 28, 592-593.	0.7	1
225	Changes in Sexual Function for Outpatients With Schizophrenia or Other Psychotic Disorders Treated With Ziprasidone in Clinical Practice Settings. Journal of Clinical Psychopharmacology, 2008, 28, 568-570.	0.7	36
226	Low-Dose Risperidone for Pathological Jealousy. Journal of Clinical Psychopharmacology, 2008, 28, 595-596.	0.7	2
227	Visual and Coenesthetic Hallucinations Associated With Modafinil. Journal of Clinical Psychopharmacology, 2008, 28, 251-252.	0.7	10
228	Persistent Suppression of Postexercise Facilitation of Motor Evoked Potentials During Alternate Phases of Bipolar Disorder. Journal of Clinical Neurophysiology, 2008, 25, 115-118.	0.9	3
229	Gabapentin in the Treatment of Mental Illness: The Echo Chamber of the Case Series. Journal of Psychiatric Practice, 2008, 14, 15-27.	0.3	9
230	Effects of Topiramate on Smoking in Patients With Schizoaffective Disorder, Bipolar Type. Journal of Clinical Psychopharmacology, 2008, 28, 247-248.	0.7	12
231	Clinical Experience With Carbamazepine Overdose. Journal of Clinical Psychopharmacology, 2008, 28, 241-243.	0.7	13
232	Myoclonus Provoked by Lamotrigine in a Bipolar Patient. Journal of Clinical Psychopharmacology, 2008, 28, 248-249.	0.7	10
233	No Effect of Spironolactone on Bulimia Nervosa Symptoms. Journal of Clinical Psychopharmacology, 2008, 28, 258-260.	0.7	5
234	Drug-Induced Liver Disease Related to Citalopram. Journal of Clinical Psychopharmacology, 2008, 28, 254-255.	0.7	10
235	Confounding Influence of Extraneous Symptoms on Clinical Global Impression Ratings for Depression. Journal of Clinical Psychopharmacology, 2008, 28, 587-589.	0.7	2
236	Nonfatal Suicidal Olanzapine Intoxication. Journal of Clinical Psychopharmacology, 2008, 28, 578.	0.7	0
237	Zotepine-Induced QTc Prolongation. Journal of Clinical Psychopharmacology, 2008, 28, 576-578.	0.7	8
238	Improved Insulin Sensitivity in 51 Nondiabetic Depressed Inpatients Remitting During Antidepressive Treatment With Mirtazapine and Venlafaxine. Journal of Clinical Psychopharmacology, 2008, 28, 581-584.	0.7	24
239	Acute Psychosis Induced by Clarithromycin in a Healthy Adult?. Journal of Clinical Psychopharmacology, 2008, 28, 579-580.	0.7	19
240	Integrating Medical and Psychiatric Care in Patients With Bipolar Disorder. Journal of Clinical Psychopharmacology, 2008, 28, 257-258.	0.7	7

#	ARTICLE	IF	CITATIONS
241	High-Dose Ziprasidone Monotherapy in Bipolar I Disorder Patients With Depressed or Mixed Episodes. Journal of Clinical Psychopharmacology, 2008, 28, 240-241.	0.7	8
242	Tardive Dystonia Associated With Low-Dose of Amisulpride. Journal of Clinical Psychopharmacology, 2008, 28, 573-574.	0.7	10
243	A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Disorder. Journal of Clinical Psychopharmacology, 2008, 28, 584-587.	0.7	44
244	Pregabalin Treatment of PosttraumaticStress Disorder. Journal of Clinical Psychopharmacology, 2008, 28, 596-597.	0.7	12
245	A Case of Venlafaxine-Induced Galactorrhea?. Journal of Clinical Psychopharmacology, 2008, 28, 580-581.	0.7	11
246	Opiate Treatment in Depression Refractory to Antidepressants and Electroconvulsive Therapy. Journal of Clinical Psychopharmacology, 2008, 28, 593-595.	0.7	78
247	Acute Dystonic Reaction After Initiating Aripiprazole Monotherapy in a 20-Year-Old Man. Journal of Clinical Psychopharmacology, 2008, 28, 245-247.	0.7	10
248	Nocturnal Enuresis After Paroxetine Abrupt Discontinuation. Journal of Clinical Psychopharmacology, 2008, 28, 589-591.	0.7	5
249	An Open-Label Study of Aripiprazole in Nonschizophrenic Crack-Dependent Patients. Journal of Clinical Psychopharmacology, 2008, 28, 570-572.	0.7	18
250	Weight Gain and First-Generation Antipsychotics. Journal of Clinical Psychopharmacology, 2008, 28, 574-576.	0.7	6
251	Catatonia and Mild Neuroleptic Malignant Syndrome After Initiation of Long-Acting Injectable Risperidone. Journal of Clinical Psychopharmacology, 2008, 28, 572-573.	0.7	10
252	Efficacy of Quetiapine Monotherapy in Rapid-Cycling Bipolar Disorder in Comparison With Sodium Valproate. Journal of Clinical Psychopharmacology, 2008, 28, 555-560.	0.7	28
253	Stimulant Dosing in the Community Treatment of Adult Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology, 2008, 28, 255-257.	0.7	2
254	Aripiprazole Efficacy in Irritability and Disruptive-Aggressive Symptoms. Journal of Clinical Psychopharmacology, 2008, 28, 243-245.	0.7	9
255	Lithium Overcomes the Influence of 5-HTTLPR Gene Polymorphism on Antidepressant Response to Sleep Deprivation. Journal of Clinical Psychopharmacology, 2008, 28, 249-251.	0.7	35
256	Aripiprazole Induced Hypersexuality in a 24-Year-Old Female Patient With Schizoaffective Disorder?. Journal of Clinical Psychopharmacology, 2008, 28, 567-568.	0.7	24
257	Duloxetine Treatment of Social Anxiety Disorder With Comorbid Major Depression. Journal of Clinical Psychopharmacology, 2008, 28, 591-592.	0.7	4
258	Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: a multicenter, open-label, randomized, comparative trial. Neuropsychiatric Disease and Treatment, 2008, 4, 675.	1.0	13

#	Article	IF	CITATIONS
259	The working alliance in supported employment for people with severe mental health problems. International Journal of Therapy and Rehabilitation, 2009, 16, 315-323.	0.1	3
260	Effectiveness of Lamotrigine in Maintaining Symptom Control in Pediatric Bipolar Disorder. Journal of Child and Adolescent Psychopharmacology, 2009, 19, 75-82.	0.7	50
261	Randomized Double-Blind Placebo-Controlled Trial of Lithium in Youths with Severe Mood Dysregulation. Journal of Child and Adolescent Psychopharmacology, 2009, 19, 61-73.	0.7	123
262	Maintenance Treatment for Patients With Bipolar I Disorder: Results From a North American Study of Quetiapine in Combination With Lithium or Divalproex (Trial 127). American Journal of Psychiatry, 2009, 166, 476-488.	4.0	207
263	Mania in the Nordic countries: Patients and treatment in the acute phase of the EMBLEM study. Nordic Journal of Psychiatry, 2009, 63, 285-291.	0.7	4
264	Lithium treatment — moderate dose use study (LiTMUS) for bipolar disorder: rationale and design. Clinical Trials, 2009, 6, 637-648.	0.7	39
265	Correlates of Treatment-Emergent Mania Associated With Antidepressant Treatment in Bipolar Depression. American Journal of Psychiatry, 2009, 166, 164-172.	4.0	161
266	Misdiagnosis of bipolar disorder as borderline personality disorder: clinical and economic consequences. World Journal of Biological Psychiatry, 2009, 10, 612-615.	1.3	8
267	Lamotrigine in bipolar disorder: Results of a mirror-image evaluation using the NIMH Lifechart-Methodology. Journal of Affective Disorders, 2009, 115, 241-245.	2.0	9
268	Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. Journal of Affective Disorders, 2009, 115, 376-385.	2.0	59
269	Bipolar disorder in the elderly; different effects of age and of age of onset. Journal of Affective Disorders, 2009, 116, 176-183.	2.0	86
270	Predictors of switching from mania to depression in a large observational study across Europe (EMBLEM). Journal of Affective Disorders, 2009, 118, 118-123.	2.0	33
271	Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. Journal of Affective Disorders, 2009, 119, 22-27.	2.0	63
272	Trauma exposure and post-traumatic stress disorder in bipolar disorder. Social Psychiatry and Psychiatric Epidemiology, 2009, 44, 1041-1049.	1.6	51
273	Bipolar disorder and dopamine dysfunction: an indirect approach focusing on tardive movement syndromes in a naturalistic setting. BMC Psychiatry, 2009, 9, 16.	1.1	13
274	Mixed states vs. pure mania in the french sample of the EMBLEM study: results at baseline and 24 months $\hat{a} \in \text{``European mania in bipolar longitudinal evaluation of medication. BMC Psychiatry, 2009, 9, 33.}$	1.1	49
275	The impact of age at onset of bipolar I disorder on functioning and clinical presentation. Acta Neuropsychiatrica, 2009, 21, 191-196.	1.0	22
276	Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatrica Scandinavica, 2009, 119, 7-14.	2.2	173

#	Article	IF	Citations
277	Preliminary results of a fineâ€grain analysis of mood swings and treatment modalities of bipolar I and II patients using the daily prospective lifeâ€chartâ€methodology. Acta Psychiatrica Scandinavica, 2009, 120, 474-480.	2.2	15
278	Psychotherapy as monotherapy for the treatment of bipolar II depression: a proof of concept study. Bipolar Disorders, 2009, 11, 89-94.	1.1	47
279	Enhancing outcomes in patients with bipolar disorder: results from the Bipolar Disorder Center for Pennsylvanians Study. Bipolar Disorders, 2009, 11, 382-390.	1.1	30
280	Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, doubleâ€blind, placeboâ€controlled study. Bipolar Disorders, 2009, 11, 687-700.	1.1	137
281	A randomized, doubleâ€blind, placeboâ€controlled study of maintenance treatment with adjunctive risperidone longâ€acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disorders, 2009, 11, 827-839.	1.1	138
282	The Clinical Global Impressions scale: errors in understanding and use. Comprehensive Psychiatry, 2009, 50, 257-262.	1.5	60
283	The psychometric validation of the Sheehan Disability Scale (SDS) in patients with bipolar disorder. Psychiatry Research, 2009, 165, 163-174.	1.7	106
284	The Mood Disorder Burden Index: A scale for assessing the burden of caregivers to adults with unipolar or bipolar disorder. Psychiatry Research, 2009, 168, 67-77.	1.7	20
285	Observational study designs for bipolar disorder â€" What can they tell us about treatment in acute mania?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 715-721.	2.5	13
286	Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis. Schizophrenia Research, 2009, 114, 17-24.	1.1	167
287	Efficacy and Safety of Lamotrigine as Add-On Treatment to Lithium in Bipolar Depression. Journal of Clinical Psychiatry, 2009, 70, 223-231.	1.1	200
288	Longer-term treatment of patients with bipolar disorder: a 9-month observational study in Central and Eastern Europe, the Middle East and Africa. Current Medical Research and Opinion, 2009, 25, 1889-1900.	0.9	5
289	Does Cannabis Use Affect Treatment Outcome in Bipolar Disorder?. Journal of Nervous and Mental Disease, 2009, 197, 35-40.	0.5	94
290	Symptom Management for Irritable Bowel Syndrome. Gastroenterology Nursing, 2009, 32, 243-255.	0.2	54
291	Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. British Journal of Psychiatry, 2009, 194, 40-48.	1.7	94
292	Effectiveness and Safety of the Combination of Fluoxetine and Olanzapine in Outpatients With Bipolar Depression. Journal of Clinical Psychopharmacology, 2009, 29, 358-361.	0.7	29
293	Course and Outcome after the First Manic Episode in Patients with Bipolar Disorder: Prospective 12-Month Data from the Systematic Treatment Optimization Program for Early Mania Project. Canadian Journal of Psychiatry, 2009, 54, 105-112.	0.9	85
294	Feasibility of a slower lamotrigine titration schedule for bipolar depression: a naturalistic study. International Clinical Psychopharmacology, 2009, 24, 105-110.	0.9	12

#	Article	IF	CITATIONS
295	Comparison of olanzapine and risperidone in the EMBLEM Study: translation of randomized controlled trial findings into clinical practice. International Clinical Psychopharmacology, 2010, 25, 257-263.	0.9	4
296	The Effectiveness of a Psychoeducational Group Program with Inpatients Being Treated for Chronic Mental Illness. Social Behavior and Personality, 2010, 38, 657-666.	0.3	6
297	Successful Treatment of Bipolar Disorder II and ADHD with a Micronutrient Formula: <i>A Case Study</i> . CNS Spectrums, 2010, 15, 289-295.	0.7	29
298	Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. International Clinical Psychopharmacology, 2010, 25, 60-67.	0.9	59
299	An Overview of Mood Disorders in the DSM-5. Current Psychiatry Reports, 2010, 12, 531-538.	2.1	23
300	Long-Term Use of Pramipexole in Bipolar Depression: A Naturalistic Retrospective Chart Review. Psychiatric Quarterly, 2010, 81, 207-213.	1.1	15
301	Psychiatric reactions to isotretinoin in patients with bipolar disorder. Journal of Affective Disorders, 2010, 122, 306-308.	2.0	44
302	Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. Journal of Affective Disorders, 2010, 121, 106-115.	2.0	147
303	Weight gain, obesity, and metabolic indices following a first manic episode: Prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). Journal of Affective Disorders, 2010, 124, 108-117.	2.0	29
304	Placebo-controlled study of quetiapine monotherapy in ambulatory bipolar spectrum disorder with moderate-to-severe hypomania or mild mania. Journal of Affective Disorders, 2010, 124, 157-163.	2.0	31
305	Functioning and symptomatic outcomes in patients with bipolar I disorder in syndromal remission: A 1-year, prospective, observational cohort study. Journal of Affective Disorders, 2010, 127, 50-57.	2.0	22
306	Does age at onset have clinical significance in older adults with bipolar disorder?. International Journal of Geriatric Psychiatry, 2010, 25, 1266-1271.	1.3	15
307	Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placeboâ€controlled pilot study. Human Psychopharmacology, 2010, 25, 126-132.	0.7	33
308	The study protocol of the Norwegian randomized controlled trial of electroconvulsive therapy in treatment resistant depression in bipolar disorder. BMC Psychiatry, 2010, 10, 16.	1.1	23
309	Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatrica Scandinavica, 2010, 122, 246-254.	2.2	33
310	Risperidone in the treatment of mixed state bipolar patients: Results from a 24â€week, multicenter, openâ€label study in Korea. Psychiatry and Clinical Neurosciences, 2010, 64, 28-37.	1.0	7
311	Conceptual and methodological issues in designing a randomized, controlled treatment trial for geriatric bipolar disorder: GERIâ€BD. Bipolar Disorders, 2010, 12, 56-67.	1.1	31
312	Randomized, placeboâ€controlled trial of flax oil in pediatric bipolar disorder. Bipolar Disorders, 2010, 12, 142-154.	1.1	83

#	ARTICLE	IF	CITATIONS
313	Antimanic and moodâ€stabilizing effect of memantine as an augmenting agent in treatmentâ€resistant bipolar disorder. Bipolar Disorders, 2010, 12, 348-349.	1.1	42
314	Pretreatment and outcome correlates of past sexual and physical trauma in 118 bipolar I disorder patients with a first episode of psychotic mania. Bipolar Disorders, 2010, 12, 244-252.	1.1	79
315	A randomized, placebo―and active ontrolled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disorders, 2010, 12, 230-243.	1.1	92
316	Doubleâ€blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. Bipolar Disorders, 2010, 12, 593-605.	1.1	71
317	The association of weight gain with mood symptoms and functional outcomes following a first manic episode: prospective 12â€month data from the Systematic Treatment Optimization Program for Early Mania (STOPâ€EM). Bipolar Disorders, 2010, 12, 616-626.	1.1	31
318	Regulation of glycogen synthase kinaseâ€3 during bipolar mania treatment. Bipolar Disorders, 2010, 12, 741-752.	1.1	74
319	Current Nosology of Treatment Resistant Depression: A Controversy Resistant to Revision. Clinical Practice and Epidemiology in Mental Health, 2010, 6, 20-24.	0.6	32
320	Acute Bipolar Depression: A Review of the Use of Olanzapine/Fluoxetine. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S1945.	0.4	1
321	A five year follow-up study of 11 patients with bipolar disorder. Jornal Brasileiro De Psiquiatria, 2010, 59, 219-222.	0.2	1
322	A Pharmacological Functional Magnetic Resonance Imaging Study Probing the Interface of Cognitive and Emotional Brain Systems in Pediatric Bipolar Disorder. Journal of Child and Adolescent Psychopharmacology, 2010, 20, 395-406.	0.7	37
323	Employment Service Provider Knowledge of Service User Assistance Needs. American Journal of Psychiatric Rehabilitation, 2010, 13, 22-39.	0.7	6
324	Twelve-month prospective, multinational, observational study of factors associated with recovery from mania in bipolar disorder in patients treated with atypical antipsychotics. World Journal of Biological Psychiatry, 2010, 11, 667-676.	1.3	5
325	Assessment of Medication Adherence in a Cohort of Patients with Bipolar Disorder. Pharmacopsychiatry, 2010, 43, 263-270.	1.7	54
326	Gender and Depressive Symptoms in 711 Patients With Bipolar Disorder Evaluated Prospectively in the Stanley Foundation Bipolar Treatment Outcome Network. American Journal of Psychiatry, 2010, 167, 708-715.	4.0	103
328	Risperidone long-acting injectable (Risperdal Consta <sup><math>\hat{A}^{\otimes}</math></sup> ) for maintenance treatment in patients with bipolar disorder. Expert Review of Neurotherapeutics, 2010, 10, 1637-1658.	1.4	41
330	Insomnia cycling with a 42-day infradian period: Evidence for two uncoupled circadian oscillators?. Sleep Medicine, 2010, 11, 343-350.	0.8	6
331	Work impairment in bipolar disorder patients – results from a two-year observational study (EMBLEM). European Psychiatry, 2010, 25, 338-344.	0.1	29
332	A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007). European Neuropsychopharmacology, 2010, 20, 776-783.	0.3	40

#	Article	IF	CITATIONS
333	The Cost of Relapse for Patients with a Manic/Mixed Episode of Bipolar Disorder in the EMBLEM Study. Pharmacoeconomics, 2010, 28, 555-566.	1.7	22
334	Subsyndromal Depressive Symptoms in Bipolar II Disorder: a Community Mental Health Services Cohort Study (SIN-DEPRES). Revista Colombiana De PsiquiatrÃa, 2011, 40, 13S-49S.	0.1	0
335	The end of the primary outcome measure: A research agenda for constructing its replacement. Clinical Psychology Review, 2011, 31, 829-838.	6.0	67
336	Differential pattern of semantic memory organization between bipolar I and II disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1053-1058.	2.5	32
337	A video clinical global impression scale (CGI) in obsessive compulsive disorder. Psychiatry Research, 2011, 186, 117-122.	1.7	9
338	Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: Results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) Study. Psychiatry Research, 2011, 190, 110-114.	1.7	96
339	Effectiveness of olanzapine monotherapy and olanzapine combination treatment in the long term following acute mania — Results of a two year observational study in bipolar disorder (EMBLEM). Journal of Affective Disorders, 2011, 131, 320-329.	2.0	16
340	2-year course of bipolar disorder type I patients in outpatient care: Factors associated with remission and functional recovery. European Neuropsychopharmacology, 2011, 21, 287-293.	0.3	60
341	N-acetylcysteine for major depressive episodes in bipolar disorder. Revista Brasileira De Psiquiatria, 2011, 33, 374-378.	0.9	99
342	Paliperidone extended-release: does it have a place in antipsychotic therapy?. Drug Design, Development and Therapy, 2011, 5, 125.	2.0	20
343	Efficacy and Tolerability of Armodafinil. Journal of Occupational and Environmental Medicine, 2011, 53, 1460-1465.	0.9	21
344	A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance. International Clinical Psychopharmacology, 2011, 26, 48-53.	0.9	61
345	Differential clinical characteristics, medication usage, and treatment response of bipolar disorder in the US versus The Netherlands and Germany. International Clinical Psychopharmacology, 2011, 26, 96-106.	0.9	54
346	Development of an Integrated Psychosocial Treatment to Address the Medical Burden Associated with Bipolar Disorder. Journal of Psychiatric Practice, 2011, 17, 224-232.	0.3	41
347	Correlates of Treatment-Emergent Mania Associated With Antidepressant Treatment in Bipolar Depression. Focus (American Psychiatric Publishing), 2011, 9, 540-548.	0.4	1
348	DSM-5 proposals for mood disorders: a cost–benefit analysis. Current Opinion in Psychiatry, 2011, 24, 1-9.	3.1	51
349	Tiagabine in the maintenance treatment of bipolar disorder. The Cochrane Library, 2011, , CD005173.	1.5	3
350	Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. Bipolar Disorders, 2011, 13, 111-117.	1.1	44

#	Article	IF	CITATIONS
351	Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disorders, 2011, 13, 87-98.	1.1	155
352	Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disorders, 2011, 13, 133-144.	1.1	101
353	Multisite, open-label, prospective trial of lamotrigine for geriatric bipolar depression: a preliminary report. Bipolar Disorders, 2011, 13, 294-302.	1.1	39
354	Suicidal attempts in bipolar disorder: results from an observational study (EMBLEM). Bipolar Disorders, 2011, 13, 377-386.	1.1	67
355	Child Mania Rating Scale-Parent Version: A valid measure of symptom change due to pharmacotherapy. Journal of Affective Disorders, 2011, 128, 112-119.	2.0	26
356	Efficacy and safety of nonbenzodiazepine hypnotics for chronic insomnia in patients with bipolar disorder. Journal of Affective Disorders, 2011, 128, 305-308.	2.0	18
357	N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. Journal of Affective Disorders, 2011, 129, 317-320.	2.0	93
358	Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: A randomized, placebo-controlled study. Journal of Affective Disorders, 2011, 129, 252-260.	2.0	60
359	Aripiprazole monotherapy in the treatment of bipolar disorder: A meta-analysis. Journal of Affective Disorders, 2011, 133, 361-370.	2.0	46
360	The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: An open label trial. Journal of Affective Disorders, 2011, 135, 389-394.	2.0	162
361	Extended-Release Quetiapine as Monotherapy for the Treatment of Adults With Acute Mania: A Randomized, Double-Blind, 3-Week Trial. Clinical Therapeutics, 2011, 33, 1643-1658.	1.1	39
362	Is it possible to assess subjective well-being among bipolar inpatients? An 18-week follow-up study. General Hospital Psychiatry, 2011, 33, 185-190.	1.2	8
363	Gender differences in outcomes of acute mania: a 12-month follow-up study. Archives of Women's Mental Health, 2011, 14, 107-113.	1.2	9
364	Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. BMC Psychiatry, 2011, 11, 101.	1.1	56
365	Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms. BMC Psychiatry, 2011, 11, 171.	1.1	18
366	Clinical management and burden of bipolar disorder: a multinational longitudinal study (WAVE-bd) Tj ETQq $1\ 1\ 0.7$	<sup>7</sup> 84314 rg 1.1	BT_{Overlock
367	Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6â€month, randomized, placeboâ€controlled, doubleâ€blind maintenance trial. Human Psychopharmacology, 2011, 26, 543-553.	0.7	32
368	Safety and efficacy of olanzapine monotherapy in treatmentâ€resistant bipolar mania: a 12â€week openâ€label study. Human Psychopharmacology, 2011, 26, 588-595.	0.7	5

#	ARTICLE	IF	CITATIONS
369	Are Clinicians' Assessments of Improvements in Children's Functioning "Global�. Journal of Clinical Child and Adolescent Psychology, 2011, 40, 281-294.	2.2	36
370	Electroconvulsive therapy for depression. The Cochrane Library, 0, , .	1.5	3
371	Effect of Micronutrients on Behavior and Mood in Adults With ADHD: Evidence From an 8-Week Open Label Trial With Natural Extension. Journal of Attention Disorders, 2011, 15, 79-91.	1.5	40
372	Oxcarbazepine for acute affective episodes in bipolar disorder. The Cochrane Library, 2011, , CD004857.	1.5	23
373	Large positive effect of lithium on prefrontal cortex N-acetylaspartate in patients with bipolar disorder: 2-centre study. Journal of Psychiatry and Neuroscience, 2012, 37, 185-192.	1.4	54
374	Chronic Mania: An Underrecognized Clinical Entity. Indian Journal of Psychological Medicine, 2012, 34, 87-89.	0.6	4
375	Týrkiye'de Bipolar I Bozukluğu Hastalarının, Sosyodemografik ve Klinik Özellikleri-HOME Çalışması. Journal of Microbiology and Biotechnology, 2012, 22, 31-42.	0.9	6
376	Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. British Journal of Psychiatry, 2012, 201, 376-382.	1.7	103
377	A Randomized Controlled Trial of Risperidone, Lithium, or Divalproex Sodium for Initial Treatment of Bipolar I Disorder, Manic or Mixed Phase, in Children and Adolescents. Archives of General Psychiatry, 2012, 69, 515.	13.8	201
378	Characteristics Associated with Inpatient Versus Outpatient Status in Older Adults with Bipolar Disorder. Journal of Geriatric Psychiatry and Neurology, 2012, 25, 62-68.	1.2	13
379	Methods to limit attrition in longitudinal comparative effectiveness trials: lessons from the Lithium Treatment – Moderate dose Use Study (LiTMUS) for bipolar disorder. Clinical Trials, 2012, 9, 94-101.	0.7	11
380	Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder. Current Medical Research and Opinion, 2012, 28, 701-713.	0.9	13
381	Predictors of Response to Ziprasidone: Results from a 6-Week Randomized Double-Blind, Placebo-Controlled Trial for Acute Depressive Mixed State. Pharmacopsychiatry, 2012, 45, 152-155.	1.7	9
382	Description of Study Population and Analysis of Factors Influencing Adherence in the Observational Italian Study "Evaluation of Pharmacotherapy Adherence in Bipolar Disorder―(EPHAR). CNS Neuroscience and Therapeutics, 2012, 18, 110-118.	1.9	25
383	Bilateral subthalamic nucleus stimulation for generalized dystonia after bilateral pallidotomy. Movement Disorders, 2012, 27, 1559-1563.	2.2	43
384	The association between insight and symptoms in bipolar inpatients: An Italian prospective study. European Psychiatry, 2012, 27, 619-624.	0.1	24
385	Achieving and Sustaining Remission in Bipolar I Disorder with Ziprasidone. Clinical Drug Investigation, 2012, 32, 747-754.	1.1	5
386	Dropout rate and associated factors in patients with bipolar disorders. Journal of Affective Disorders, 2012, 141, 47-54.	2.0	25

#	Article	IF	CITATIONS
387	Respondent and item level patterns of response of aripiprazole in the acute treatment of pediatric bipolar I disorder. Journal of Affective Disorders, 2012, 143, 231-235.	2.0	7
388	Subthreshold symptoms and time to relapse/recurrence in a community cohort of bipolar disorder outpatients. Journal of Affective Disorders, 2012, 143, 160-165.	2.0	47
389	Clinical factors leading to lamotrigine prescription in bipolar outpatients: Subanalysis of the SIN-DEPRES study. Journal of Affective Disorders, 2012, 143, 102-108.	2.0	14
390	Treatment Moderators and Predictors of Outcome in the Treatment of Early Age Mania (TEAM) Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2012, 51, 867-878.	0.3	47
391	Association between tobacco smoking and bipolar affective disorder: clinical, epidemiological, cross-sectional, retrospective study in outpatients. Comprehensive Psychiatry, 2012, 53, 269-274.	1.5	30
392	Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial. BMC Medicine, 2012, 10, 91.	2.3	81
393	Lamotrigine as addâ€on treatment to lithium and divalproex: lessons learned from a doubleâ€blind, placeboâ€controlled trial in rapidâ€cycling bipolar disorder. Bipolar Disorders, 2012, 14, 780-789.	1.1	29
394	Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder. Journal of Affective Disorders, 2012, 142, 36-44.	2.0	33
395	Anxiety as a marker of severity in acute mania. Acta Psychiatrica Scandinavica, 2012, 126, 351-355.	2.2	13
396	Tiagabine for acute affective episodes in bipolar disorder. The Cochrane Library, 2012, 12, CD004694.	1.5	6
397	Depressive symptoms in first episode schizophrenia spectrum disorder. Schizophrenia Research, 2012, 134, 20-26.	1.1	71
398	Differentiating schizoaffective and bipolar I disorder in first-episode psychotic mania. Schizophrenia Research, 2012, 140, 31-36.	1.1	14
399	The Role of Memantine in the Treatment of Psychiatric Disorders Other Than the Dementias. CNS Drugs, 2012, 26, 663-690.	2.7	257
400	Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice. BMC Psychiatry, 2012, 12, 228.	1.1	20
401	A 6 Week Randomized Double-Blind Placebo-Controlled Trial of Ziprasidone for the Acute Depressive Mixed State. PLoS ONE, 2012, 7, e34757.	1.1	56
402	Memantine: A New Mood Stabilizer for Treatment-Resistant Bipolar Disorders. , 2012, , .		2
403	A Randomized Controlled Pilot Study of Cognitive Behavioral Social Skills Training (Korean version) for Middle- or Older-Aged Patients with Schizophrenia: A Pilot Study. Journal of Korean Neuropsychiatric Association, 2012, 51, 192.	0.2	3
404	Effectiveness of two formulations of oral olanzapine in patients with schizophrenia or bipolar disorder in a natural setting: results from a 1â€year European observational study. Human Psychopharmacology, 2012, 27, 284-294.	0.7	5

#	Article	IF	CITATIONS
405	Shaken but unstirred? Effects of micronutrients on stress and trauma after an earthquake: RCT evidence comparing formulas and doses. Human Psychopharmacology, 2012, 27, 440-454.	0.7	44
406	A global measure to assess switching antipsychotic medications in the treatment of schizophrenia. Human Psychopharmacology, 2012, 27, 455-463.	0.7	7
407	Is melatonin an adjunctive stabilizer?. Psychiatry and Clinical Neurosciences, 2012, 66, 82-83.	1.0	18
408	Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: A randomized, double-blind, dose-response study. Journal of Affective Disorders, 2012, 136, e51-e60.	2.0	49
409	The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: Findings from a 12-month naturalistic trial. Journal of Affective Disorders, 2012, 136, 163-166.	2.0	55
410	Subthreshold symptoms in bipolar disorder: Impact on neurocognition, quality of life and disability. Journal of Affective Disorders, 2012, 136, 650-659.	2.0	156
411	Affective temperaments in clinical practice: A validation study in mood disorders. Journal of Affective Disorders, 2012, 136, 577-580.	2.0	15
412	Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: A randomized, double-blind, placebo- and haloperidol-controlled study. Journal of Affective Disorders, 2012, 136, 476-484.	2.0	24
413	Mixed depression: A study of its phenomenology and relation to treatment response. Journal of Affective Disorders, 2012, 136, 1059-1061.	2.0	24
414	Rethinking the classification of mixed affective episodes in ICD-11. Journal of Affective Disorders, 2012, 138, 170-172.	2.0	9
415	A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. Journal of Affective Disorders, 2012, 138, 247-258.	2.0	63
416	Can a targeted psychological intervention be effective for young people following a first manic episode? Results from an 18â€month pilot study. Microbial Biotechnology, 2012, 6, 380-388.	0.9	34
417	Development of a clinical global impression scale for fatigue. Journal of Psychiatric Research, 2012, 46, 370-374.	1.5	25
418	Pilot study of the efficacy of double-blind, placebo-controlled one-week olanzapine stabilization therapy in heterogeneous symptomatic bipolar disorder patients. Journal of Psychiatric Research, 2012, 46, 920-926.	1.5	3
419	A randomized pilot study of psychotherapy and quetiapine for the acute treatment of bipolar II depression. Bipolar Disorders, 2012, 14, 211-216.	1.1	45
420	Sixâ€month outcomes of customized adherence enhancement (CAE) therapy in bipolar disorder. Bipolar Disorders, 2012, 14, 291-300.	1.1	31
421	Number of prior episodes and the presence of depressive symptoms are associated with longer length of stay for patients with acute manic episodes. Annals of General Psychiatry, 2012, 11, 7.	1.2	19
422	A structured interview guide for global impressions: increasing reliability and scoring accuracy for CNS trials. Annals of General Psychiatry, 2013, 12, 2.	1.2	11

#	Article	IF	Citations
423	Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study. BMC Psychiatry, 2013, 13, 138.	1.1	20
424	Methylphenidate in mania project (MEMAP): study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate. BMC Psychiatry, 2013, 13, 71.	1.1	15
425	Do current screening recommendations allow for early detection of lithium-induced hyperparathyroidism in patients with bipolar disorder?. International Journal of Bipolar Disorders, 2013, 1, 7.	0.8	5
426	Association of exercise with quality of life and mood symptoms in a comparative effectiveness study of bipolar disorder. Journal of Affective Disorders, 2013, 151, 722-727.	2.0	76
427	Characteristics of responders and non-responders to risperidone monotherapy or placebo in co-occurring bipolar disorder and anxiety disorder. European Psychiatry, 2013, 28, 190-196.	0.1	4
428	Treatment adherence towards prescribed medications in bipolar-II acute depressed patients: Relationship with cyclothymic temperament and "therapeutic sensation seeking―in response towards subjective intolerance to pain. Journal of Affective Disorders, 2013, 151, 596-604.	2.0	39
429	Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient. Journal of Affective Disorders, 2013, 145, 83-94.	2.0	39
430	To a broader concept of remission: Rating the health-related quality of life in bipolar disorder. Journal of Affective Disorders, 2013, 150, 673-676.	2.0	6
431	Comparably high retention and low relapse rates in different subpopulations of bipolar patients in a German non-interventional study. BMC Psychiatry, 2013, 13, 193.	1.1	6
432	Clinical Significance of Treatment Effects with Aripiprazole versus Placebo in a Study of Manic or Mixed Episodes Associated with Pediatric Bipolar I Disorder. Journal of Child and Adolescent Psychopharmacology, 2013, 23, 72-79.	0.7	24
433	Brain-derived neurotrophic factor val66met genotype and early life stress effects upon bipolar course. Journal of Psychiatric Research, 2013, 47, 252-258.	1.5	44
434	Lithium Treatment Moderate-Dose Use Study (LiTMUS) for Bipolar Disorder: A Randomized Comparative Effectiveness Trial of Optimized Personalized Treatment With and Without Lithium. American Journal of Psychiatry, 2013, 170, 102-110.	4.0	80
435	Attention Deficit/Hyperactivity Disorder symptoms in Italian bipolar adult patients: A preliminary report. Journal of Affective Disorders, 2013, 149, 430-434.	2.0	44
436	Relationship between the clinical global impression of severity for schizoaffective disorder scale and established mood scales for mania and depression. Journal of Affective Disorders, 2013, 150, 17-22.	2.0	16
437	Neural activity to intense positive versus negative stimuli can help differentiate bipolar disorder from unipolar major depressive disorder in depressed adolescents: A pilot fMRI study. Psychiatry Research - Neuroimaging, 2013, 214, 277-284.	0.9	46
438	The sick role, illness cognitions and outcomes in bipolar disorder. Journal of Affective Disorders, 2013, 146, 146-149.	2.0	16
439	Superior chronic tolerability of adjunctive modafinil compared to pramipexole in treatment-resistant bipolar disorder. Journal of Affective Disorders, 2013, 150, 130-135.	2.0	9
440	Predictors of employment in bipolar disorder: A systematic review. Journal of Affective Disorders, 2013, 145, 156-164.	2.0	77

#	Article	IF	CITATIONS
441	A preliminary open trial of nefazodone added to mood stabilizers for bipolar depression. Journal of Affective Disorders, 2013, 144, 176-178.	2.0	5
442	What goes up must come down: The burden of bipolar depression in youth. Journal of Affective Disorders, 2013, 150, 1048-1054.	2.0	14
443	An open trial of pregabalin as an acute and maintenance adjunctive treatment for outpatients with treatment resistant bipolar disorder. Journal of Affective Disorders, 2013, 147, 407-410.	2.0	29
444	The Medication Recommendation Tracking Form: A novel tool for tracking changes in prescribed medication, clinical decision making, and use in comparative effectiveness research. Journal of Psychiatric Research, 2013, 47, 1686-1693.	1.5	14
445	Continuous circular cycling in bipolar disorder as a predictor of poor outcome. Journal of Affective Disorders, 2013, 150, 823-828.	2.0	8
446	1281 $\hat{a}$ €" Association between tobacco smoking and bipolar affective disorder: clinical, epidemiological, cross-sectional, retrospective study in outpatients. European Psychiatry, 2013, 28, 1.	0.1	0
447	The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a doubleâ€blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144). Bipolar Disorders, 2013, 15, 100-109.	1.1	60
448	Neural correlates of treatment response in depressed bipolar adolescents during emotion processing. Brain Imaging and Behavior, 2013, 7, 227-235.	1.1	24
449	First controlled treatment trial of bipolar II hypomania with mixed symptoms: Quetiapine versus placebo. Journal of Affective Disorders, 2013, 150, 37-43.	2.0	28
450	Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd). International Journal of Neuropsychopharmacology, 2013, 16, 1719-1732.	1.0	76
451	Aripiprazole for the treatment of pediatric bipolar I disorder: a 30â€week, randomized, placeboâ€controlled study. Bipolar Disorders, 2013, 15, 138-149.	1.1	62
452	Differences between first episode schizophrenia and schizoaffective disorder. Schizophrenia Research, 2013, 147, 169-174.	1.1	18
453	Changes in saccadic eye movement (SEM) and quantitative EEG parameter in bipolar patients. Journal of Affective Disorders, 2013, 145, 378-385.	2.0	19
454	Nutrition, Exercise, and Wellness Treatment in bipolar disorder: proof of concept for a consolidated intervention. International Journal of Bipolar Disorders, 2013, 1, 24.	0.8	65
455	Use of Treatment Services in a Comparative Effectiveness Study of Bipolar Disorder. Psychiatric Services, 2013, 64, 1119-1126.	1.1	3
456	Use of adjunctive stimulants in adult bipolar depression. International Journal of Neuropsychopharmacology, 2013, 16, 55-68.	1.0	26
457	Prescribing patterns of lithium or lithium+valproate in manic or mixed episodes. International Clinical Psychopharmacology, 2013, 28, 305-311.	0.9	11
458	Bipolar depression in children and adolescents. CNS Spectrums, 2013, 18, 209-213.	0.7	13

#	Article	IF	CITATIONS
459	Patterns of pharmacological maintenance treatment in a community mental health services bipolar disorder cohort study (SIN-DEPRES). International Journal of Neuropsychopharmacology, 2013, 16, 513-523.	1.0	33
460	Impaired fixation to eyes during facial emotion labelling in children with bipolar disorder or severe mood dysregulation. Journal of Psychiatry and Neuroscience, 2013, 38, 407-416.	1.4	25
461	Group Interpersonal and Social Rhythm Therapy for Bipolar Depression. Perspectives in Psychiatric Care, 2013, 49, n/a-n/a.	0.9	23
462	Occupational disability in bipolar disorder: analysis of predictors of being on severe disablement benefit (PREBIS study data). Acta Psychiatrica Scandinavica, 2013, 127, 403-411.	2.2	54
463	A BRIEF COGNITIVE-BEHAVIORAL INTERVENTION FOR TREATING DEPRESSION AND PANIC DISORDER IN PATIENTS WITH NONCARDIAC CHEST PAIN: A 24-WEEK RANDOMIZED CONTROLLED TRIAL. Depression and Anxiety, 2013, 30, 670-678.	2.0	31
464	Short TE <sup>7</sup> Liâ€MRS confirms Biâ€exponential lithium T2 relaxation in humans and clearly delineates two patient subtypes. Journal of Magnetic Resonance Imaging, 2013, 37, 1451-1459.	1.9	4
465	A preliminary investigation on the efficacy of <i>N</i> -acetyl cysteine for mania or hypomania. Australian and New Zealand Journal of Psychiatry, 2013, 47, 564-568.	1.3	50
466	Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort. International Journal of Methods in Psychiatric Research, 2013, 22, 46-58.	1.1	78
467	Neural Correlates of Treatment in Adolescents with Bipolar Depression During Response Inhibition. Journal of Child and Adolescent Psychopharmacology, 2013, 23, 214-221.	0.7	46
468	Use of Micronutrients Attenuates Cannabis and Nicotine Abuse as Evidenced From a Reversal Design: A Case Study. Journal of Psychoactive Drugs, 2013, 45, 168-178.	1.0	6
469	Safety, Tolerability, and Efficacy of Quetiapine in Youth with Schizophrenia or Bipolar I Disorder: A 26-Week, Open-Label, Continuation Study. Journal of Child and Adolescent Psychopharmacology, 2013, 23, 490-501.	0.7	22
470	Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study. Neuropsychiatric Disease and Treatment, 2013, 9, 243.	1.0	53
471	Correlates of current suicide risk among Thai patients with bipolar I disorder: findings from the Thai Bipolar Disorder Registry. Neuropsychiatric Disease and Treatment, 2013, 9, 1751.	1.0	10
472	Time to relapse and remission of bipolar disorder: findings from a 1-year prospective study in Thailand. Neuropsychiatric Disease and Treatment, 2013, 9, 1249.	1.0	8
473	Mood self-assessment in bipolar disorder: a comparison between patients in mania, depression, and euthymia. Trends in Psychiatry and Psychotherapy, 2013, 35, 141-145.	0.4	10
474	Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open-label, observational study. Neuropsychiatric Disease and Treatment, 2013, 9, 197.	1.0	9
475	Quetiapine for acute bipolar depression: a systematic review and meta-analysis. Drug Design, Development and Therapy, 2014, 8, 827.	2.0	67
476	Efficacy of Olanzapine for Treating Depressive Episodes in Bipolar Disorder. Clinical Neuropsychopharmacology and Therapeutics, 2014, 5, 11-17.	0.3	2

#	Article	IF	CITATIONS
477	Risk factors for an anxiety disorder comorbidity among Thai patients with bipolar disorder: results from the Thai Bipolar Disorder Registry. Neuropsychiatric Disease and Treatment, 2014, 10, 803.	1.0	7
478	Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LiTMUS). Pharmacogenomics Journal, 2014, 14, 182-191.	0.9	37
479	Observational study to evaluate the clinical benefit of lamotrigine add-on therapy in bipolar patients in a naturalistic treatment setting. Asia-Pacific Psychiatry, 2014, 6, 334-341.	1.2	4
480	Corrigendum to "Effectiveness of the Extended Release Formulation of Quetiapine as Monotherapy for the Treatment of Acute Bipolar Depression―[J. Affect. Disord. 121 (1–2) (2010) 106–115]. Journal of Affective Disorders, 2014, 168, 485-493.	2.0	14
483	Revelation, delusion or disillusion: subjective interpretation of religious and spiritual experiences in bipolar disorder. Mental Health, Religion and Culture, 2014, 17, 615-628.	0.6	18
484	Psychological functioning 1 year after a brief intervention using micronutrients to treat stress and anxiety related to the 2011 Christchurch earthquakes: a naturalistic followâ€up. Human Psychopharmacology, 2014, 29, 230-243.	0.7	21
485	The potential role of atypical antipsychotics in the treatment of panic disorder. Human Psychopharmacology, 2014, 29, 405-413.	0.7	12
486	Current landscape, unmet needs, and future directions for treatment of bipolar depression. Journal of Affective Disorders, 2014, 169, S17-S23.	2.0	29
487	Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study. International Journal of Bipolar Disorders, 2014, 2, 14.	0.8	33
488	The Reliability of Self-assessment of Affective State in Different Phases of Bipolar Disorder. Journal of Nervous and Mental Disease, 2014, 202, 386-390.	0.5	11
489	A novel application of the <i>Intent to Attend</i> assessment to reduce bias due to missing data in a randomized controlled clinical trial. Clinical Trials, 2014, 11, 494-502.	0.7	9
490	Prophylactic lithium treatment and cognitive performance in patients with a long history of bipolar illness: no simple answers in complex disease-treatment interplay. International Journal of Bipolar Disorders, $2014, 2, 1$ .	0.8	28
491	Predictors of substance use reduction in an epidemiological firstâ€episode psychosis cohort. Microbial Biotechnology, 2014, 8, 358-365.	0.9	6
492	Characteristics of stress-coping behaviors in patients with bipolar disorders. Psychiatry Research, 2014, 218, 69-74.	1.7	14
493	Residual symptoms and functional performance in a large sample of euthymic bipolar patients in France (the OPTHYMUM study). Journal of Affective Disorders, 2014, 159, 94-102.	2.0	33
494	Val66Met polymorphism and serum brainâ€derived neurotrophic factor in bipolar disorder: an openâ€label trial. Acta Psychiatrica Scandinavica, 2014, 129, 393-400.	2.2	23
495	Patient satisfaction with psychotropic drugs: Validation of the PAtient SAtisfaction with Psychotropic (PASAP) scale in patients with bipolar disorder. European Psychiatry, 2014, 29, 183-190.	0.1	7
496	Effect of alcohol use on the course of bipolar disorder: oneâ€year followâ€up study using the daily prospective Life Chart method. Bipolar Disorders, 2014, 16, 400-409.	1.1	6

#	Article	IF	CITATIONS
497	Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: Results from the Bipolar CHOICE trial. Journal of Affective Disorders, 2014, 161, 30-35.	2.0	18
498	Lurasidone Monotherapy in the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Study. American Journal of Psychiatry, 2014, 171, 160-168.	4.0	271
499	Differential patterns of neuropsychological performance in the euthymic and depressive phases of bipolar disorders. Psychiatry and Clinical Neurosciences, 2014, 68, 515-523.	1.0	11
500	Medication adherence in a comparative effectiveness trial for bipolar disorder. Acta Psychiatrica Scandinavica, 2014, 129, 359-365.	2.2	31
501	Oneâ€year rehospitalization rates of patients with firstâ€episode bipolar mania receiving lithium or valproate and adjunctive atypical antipsychotics. Psychiatry and Clinical Neurosciences, 2014, 68, 418-424.	1.0	10
502	General medical burden in bipolar disorder: findings from the Li <scp>TMUS</scp> comparative effectiveness trial. Acta Psychiatrica Scandinavica, 2014, 129, 24-34.	2.2	74
503	Lamotrigine Treatment of Adolescents with Unipolar and Bipolar Depression: A Retrospective Chart Review. Journal of Child and Adolescent Psychopharmacology, 2014, 24, 285-287.	0.7	10
504	Efficacy and Safety of Extended-Release Quetiapine Fumarate in Youth with Bipolar Depression: An 8 Week, Double-Blind, Placebo-Controlled Trial. Journal of Child and Adolescent Psychopharmacology, 2014, 24, 325-335.	0.7	65
505	Child- and Family-Focused Cognitive-Behavioral Therapy for Pediatric Bipolar Disorder: A Randomized Clinical Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 1168-1178.e1.	0.3	78
506	Mindfulness-based cognitive therapy versus psychoeducational intervention in bipolar outpatients with sub-threshold depressive symptoms: a randomized controlled trial. BMC Psychiatry, 2014, 14, 215.	1.1	19
507	Saving time and money: a validation of the self ratings on the prospective NIMH life-chart method (NIMH-LCM). BMC Psychiatry, 2014, 14, 130.	1.1	20
508	Treatment of bipolar disorder in the Netherlands and concordance with treatment guidelines: study protocol of an observational, longitudinal study on naturalistic treatment of bipolar disorder in everyday clinical practice. BMC Psychiatry, 2014, 14, 58.	1.1	7
509	Effectiveness of the Dader Method for pharmaceutical care in patients with bipolar I disorder: EMDADER-TAB: study protocol for a randomized controlled trial. Trials, 2014, 15, 174.	0.7	9
510	Trends in pharmacotherapy in patients referred to a bipolar specialty clinic, 2000–2011. Journal of Affective Disorders, 2014, 155, 283-287.	2.0	33
511	Eye movement desensitization and reprocessing therapy in subsyndromal bipolar patients with a history of traumatic events: A randomized, controlled pilot-study. Psychiatry Research, 2014, 219, 122-128.	1.7	76
512	Quality of life in bipolar and schizoaffective disorder â€" A naturalistic approach. Comprehensive Psychiatry, 2014, 55, 1540-1545.	1.5	16
513	rTMS in resistant mixed states: An exploratory study. Journal of Affective Disorders, 2014, 157, 66-71.	2.0	18
514	The Efficacy of Adjunctive <i>N</i> -Acetylcysteine in Major Depressive Disorder. Journal of Clinical Psychiatry, 2014, 75, 628-636.	1.1	142

#	Article	IF	CITATIONS
515	Measurements of Response, Remission, and Recovery in Schizophrenia and Examples for Their Clinical Application. Journal of Clinical Psychiatry, 2014, 75, 8-14.	1.1	113
516	Assessing the affective load in the narratives of women suffering from fibromyalgia: the clinicians' appraisal. Health Expectations, 2015, 18, 3325-3335.	1.1	0
517	Data quality indicators for daily life chart methodology: prospective self-ratings of bipolar disorder and alcohol use. BMC Research Notes, 2015, 8, 473.	0.6	3
518	Identifying and describing patients' learning experiences towards selfâ€management of bipolar disorders: a phenomenological study. Journal of Psychiatric and Mental Health Nursing, 2015, 22, 801-810.	1.2	9
519	Efficacy of Tranylcypromine in Bipolar Depression. Journal of Clinical Psychopharmacology, 2015, 35, 700-705.	0.7	27
520	Insight in bipolar disorder: a comparison between mania, depression and euthymia using the Insight Scale for Affective Disorders. Trends in Psychiatry and Psychotherapy, 2015, 37, 152-156.	0.4	16
521	Evaluating depressive symptoms in mania: a naturalistic study of patients with bipolar disorder. Neuropsychiatric Disease and Treatment, 2015, $11$ , $1137$ .	1.0	24
522	Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression. Revista Brasileira De Psiquiatria, 2015, 37, 03-12.	0.9	38
523	Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar <scp>CHOICE</scp> ). Bipolar Disorders, 2015, 17, 212-223.	1.1	77
524	Placebo-Controlled Trial of Valproic Acid Versus Risperidone in Children 3–7 Years of Age with Bipolar I Disorder. Journal of Child and Adolescent Psychopharmacology, 2015, 25, 306-313.	0.7	17
525	Collaborative care for patients with bipolar disorder: randomised controlled trial. British Journal of Psychiatry, 2015, 206, 393-400.	1.7	29
526	Treatment Implications of Predominant Polarity and the Polarity Index: A Comprehensive Review. International Journal of Neuropsychopharmacology, 2015, 18, pyu079-pyu079.	1.0	34
527	Los costos y consumo de recursos sanitarios asociados a episodios manÃacos en la práctica clÃnica diaria: el estudio MANACOR. Revista De PsiquiatrÃa Y Salud Mental, 2015, 8, 55-64.	1.0	12
528	Olanzapine/Fluoxetine Combination in Children and Adolescents With Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54, 217-224.	0.3	62
529	Insight Across the Different Mood States of Bipolar Disorder. Psychiatric Quarterly, 2015, 86, 395-405.	1.1	36
530	Treatment of Psychosis and Mania in the Postpartum Period. American Journal of Psychiatry, 2015, 172, 115-123.	4.0	103
531	Serum uric acid levels and different phases of illness in bipolar I patients treated with lithium. Psychiatry Research, 2015, 225, 604-608.	1.7	26
532	Cannabinoids and bipolar disorder. , 2015, , 205-225.		1

#	Article	IF	CITATIONS
533	Course and outcome following a first episode of mania: Four-year prospective data from the Systematic Treatment Optimization Program (STOP-EM). Journal of Affective Disorders, 2015, 175, 411-417.	2.0	18
534	Treatment-Resistant Bipolar Depression: A Randomized Controlled Trial of Electroconvulsive Therapy Versus Algorithm-Based Pharmacological Treatment. American Journal of Psychiatry, 2015, 172, 41-51.	4.0	135
535	Treatment Moderators of Child- and Family-Focused Cognitive-Behavioral Therapy for Pediatric Bipolar Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54, 116-125.	0.3	32
536	Asenapine prescribing patterns in the treatment of manic in- and outpatients: Results from the MANACOR study. European Psychiatry, 2015, 30, 528-534.	0.1	17
537	Psychotherapy use in bipolar disorder: Association with functioning and illness severity. Australian and New Zealand Journal of Psychiatry, 2015, 49, 453-461.	1.3	21
538	Cannabis and bipolar disorder: does quitting cannabis use during manic/mixed episode improve clinical/functional outcomes?. Acta Psychiatrica Scandinavica, 2015, 131, 100-110.	2.2	40
539	The Treatment of Preschool Mood Disorders. Current Treatment Options in Psychiatry, 2015, 2, 57-72.	0.7	1
540	Rating Scales in Bipolar Disorder. , 2015, , 105-136.		18
541	Predictors of functional outcome after a manic episode. Journal of Affective Disorders, 2015, 182, 121-125.	2.0	16
542	Lithium Treatment Moderate-Dose Use Study (LiTMUS) for Bipolar Disorder: A Randomized Comparative Effectiveness Trial of Optimized Personalized Treatment With and Without Lithium. Focus (American) Tj ETQq1 1	. 007.84314	1 ngBT /Over
543	The real world cost and health resource utilization associated to manic episodes: The MANACOR study. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2015, 8, 55-64.	0.2	1
544	A randomised trial of nutrient supplements to minimise psychological stress after a natural disaster. Psychiatry Research, 2015, 228, 373-379.	1.7	31
545	Asenapine in the treatment of older adults with bipolar disorder. International Journal of Geriatric Psychiatry, 2015, 30, 710-719.	1.3	31
546	Childhood-compared to adolescent-onset bipolar disorder has more statistically significant clinical correlates. Journal of Affective Disorders, 2015, 179, 114-120.	2.0	40
547	Cross-cultural adaptation, validation and factor structure of the Insight Scale for Affective Disorders. Journal of Affective Disorders, 2015, 178, 181-187.	2.0	8
548	Collaborative care for patients with bipolar disorder: Effects on functioning and quality of life. Journal of Affective Disorders, 2015, 179, 14-22.	2.0	28
549	An exploratory study of responses to low-dose lithium in African Americans and Hispanics. Journal of Affective Disorders, 2015, 178, 224-228.	2.0	9
551	Prevalence and risk factors for suicidal behavior in young people presenting with first-episode psychosis in Hong Kong: a 3-year follow-up study. Social Psychiatry and Psychiatric Epidemiology, 2015, 50, 219-226.	1.6	27

#	Article	IF	CITATIONS
552	Predictors and Moderators of Clinical Outcomes in Adolescents with Severe Mental Disorders After an Assertive Community Treatment. Child Psychiatry and Human Development, 2015, 46, 997-1005.	1.1	3
553	Increasing the Sensitivity of Measures to Change. Prevention Science, 2015, 16, 978-986.	1.5	43
554	Adjunctive lisdexamfetamine in bipolar depression. International Clinical Psychopharmacology, 2015, 30, 6-13.	0.9	31
556	Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54, 1032-1041.	0.3	50
557	Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study. BMC Psychiatry, 2015, 15, 189.	1.1	82
558	Bipolar disorder and self-stigma: A comparison with schizophrenia. Journal of Affective Disorders, 2015, 184, 209-215.	2.0	45
559	The Working Alliance Between Patients With Bipolar Disorder and the Nurse: Helpful and Obstructive Elements During a Depressive Episode From the Patients' Perspective. Archives of Psychiatric Nursing, 2015, 29, 290-296.	0.7	4
560	An Integrated Risk Reduction Intervention can reduce body mass index in individuals being treated for bipolar I disorder: results from a randomized trial. Bipolar Disorders, 2015, 17, 424-437.	1.1	35
561	American tertiary clinic-referred bipolar II disorder compared to bipolar I disorder: More severe in multiple ways, but less severe in a few other ways. Journal of Affective Disorders, 2015, 188, 257-262.	2.0	40
562	Adjunctive Maintenance Lamotrigine for Pediatric Bipolar I Disorder: A Placebo-Controlled, Randomized Withdrawal Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54, 1020-1031.e3.	0.3	37
563	Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial. European Psychiatry, 2015, 30, 975-982.	0.1	24
564	A clinical measure of suicidal ideation, suicidal behavior, and associated symptoms in bipolar disorder: Psychometric properties of the Concise Health Risk Tracking Self-Report (CHRT-SR). Journal of Psychiatric Research, 2015, 71, 126-133.	1.5	32
565	Treatment of Early-Age Mania: Outcomes for Partial and Nonresponders to Initial Treatment. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54, 1008-1019.	0.3	22
566	Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: Experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I. Journal of Affective Disorders, 2015, 174, 70-82.	2.0	19
567	Two years' outcome of acute mania in bipolar disorder: different effects of age and age of onset. International Journal of Geriatric Psychiatry, 2015, 30, 201-209.	1.3	47
568	Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Chinese subpopulation analysis of a double-blind, randomized, placebo-controlled study. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 2077-2087.	1.0	10
569	An Open Trial of Lurasidone as an Acute and Maintenance Adjunctive Treatment for Outpatients With Treatment-Resistant Bipolar Disorder. Journal of Clinical Psychopharmacology, 2016, 36, 88-89.	0.7	9
570	Adaptive Interventions in Child and Adolescent Mental Health. Journal of Clinical Child and Adolescent Psychology, 2016, 45, 383-395.	2.2	61

#	Article	IF	CITATIONS
571	Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder. Acta Psychiatrica Scandinavica, 2016, 133, 144-153.	2.2	44
572	Safety and effectiveness of divalproex sodium extended release containing regimen in Indian patients with bipolar I disorder in continuation phase: Results of EASED registry. Asian Journal of Psychiatry, 2016, 20, 32-38.	0.9	2
573	The long-term outcomes of an effectiveness trial of group versus individual psychoeducation for bipolar disorders. Journal of Affective Disorders, 2016, 202, 32-38.	2.0	15
574	Current irritability robustly related to current and prior anxiety in bipolar disorder. Journal of Psychiatric Research, 2016, 79, 101-107.	1.5	11
575	Insight in bipolar mania: evaluation of its heterogeneity and correlation with clinical symptoms. Journal of Affective Disorders, 2016, 199, 95-98.	2.0	16
576	Electrical mapping in bipolar disorder patients during the oddball paradigm. Journal of Psychiatric Research, 2016, 72, 64-71.	1.5	11
577	The Pharmacogenomics of Bipolar Disorder study (PGBD): identification of genes for lithium response in a prospective sample. BMC Psychiatry, 2016, 16, 129.	1.1	61
578	Gender by onset age interaction may characterize distinct phenotypic subgroups in bipolar patients. Journal of Psychiatric Research, 2016, 76, 128-135.	1.5	10
579	Mediators in the randomized trial of Child- and Family-Focused Cognitive-Behavioral Therapy for pediatric bipolar disorder. Behaviour Research and Therapy, 2016, 85, 60-71.	1.6	18
580	Tracking medication changes to assess outcomes in comparative effectiveness research: A bipolar CHOICE study. Journal of Affective Disorders, 2016, 205, 159-164.	2.0	7
581	Advanced Circadian Phase in Mania and Delayed Circadian Phase in Mixed Mania and Depression Returned to Normal after Treatment of Bipolar Disorder. EBioMedicine, 2016, 11, 285-295.	2.7	111
582	Trait-related alterations of N-acetylaspartate in euthymic bipolar patients: A longitudinal proton magnetic resonance spectroscopy study. Journal of Affective Disorders, 2016, 206, 315-320.	2.0	13
583	Current irritability associated with hastened depressive recurrence and delayed depressive recovery in bipolar disorder. International Journal of Bipolar Disorders, 2016, 4, 15.	0.8	8
584	Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial. Paediatric Drugs, 2016, 18, 367-378.	1.3	22
585	Medication Adherence Among Adolescents with Bipolar Disorder. Journal of Child and Adolescent Psychopharmacology, 2016, 26, 864-872.	0.7	20
586	Developing a Virtual Reality-Based Vocational Rehabilitation Training Program for Patients with Schizophrenia. Cyberpsychology, Behavior, and Social Networking, 2016, 19, 686-691.	2.1	29
587	Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study. Journal of Neurodevelopmental Disorders, 2016, 8, 1.	1.5	69
588	More inclusive bipolar mixed depression definitions by requiring fewer nonâ€overlapping mood elevation symptoms. Acta Psychiatrica Scandinavica, 2016, 134, 189-198.	2.2	11

#	Article	IF	CITATIONS
589	Differential prevalence and demographic and clinical correlates of second-generation antipsychotic use in bipolar I versus bipolar II disorder. Journal of Psychiatric Research, 2016, 76, 52-58.	1.5	4
590	Clinical correlates of sustained response to individual drugs used in naturalistic treatment of patients with bipolar disorder. Comprehensive Psychiatry, 2016, 66, 146-156.	1.5	25
591	Different characteristics associated with suicide attempts among bipolar I versus bipolar II disorder patients. Journal of Psychiatric Research, 2016, 76, 94-100.	1.5	22
592	A tool to predict suicidal ideation and behavior in bipolar disorder: The Concise Health Risk Tracking Self-Report. Journal of Affective Disorders, 2016, 192, 212-218.	2.0	22
593	Efficacy and safety of quetiapine extended release monotherapy in bipolar depression: a multi-center, randomized, double-blind, placebo-controlled trial. Psychopharmacology, 2016, 233, 1289-1297.	1.5	32
594	Asenapine: Efficacy and safety of 5 and 10 mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder. Journal of Affective Disorders, 2016, 190, 103-110.	2.0	29
595	Type 2 diabetes and pre-diabetic abnormalities in patients with bipolar disorders. Journal of Affective Disorders, 2016, 189, 240-245.	2.0	17
596	Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial. Molecular Psychiatry, 2016, 21, 1050-1056.	4.1	42
597	White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder. Australian and New Zealand Journal of Psychiatry, 2017, 51, 355-365.	1.3	22
598	Correlation Between Insight Level and Suicidal Behavior/Ideation in Bipolar Depression. Psychiatric Quarterly, 2017, 88, 47-53.	1.1	14
599	Performance of Bipolar Disorder Patients in Attention Testing: Comparison with Normal Controls and Among Manic, Depressive, and Euthymic Phases. Psychiatric Quarterly, 2017, 88, 55-63.	1.1	8
600	Adolescent and Familyâ€focused Cognitive–behavioural Therapy for Paediatric Bipolar Disorders: A Case Series. Clinical Psychology and Psychotherapy, 2017, 24, 589-617.	1.4	7
601	Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens via Population Pharmacokinetics/Pharmacodynamics. Clinical Pharmacokinetics, 2017, 56, 77-90.	1.6	36
602	Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol do not affect 6-month mood-stabilizing treatment outcome among 482 patients with bipolar disorder. Depression and Anxiety, 2017, 34, 281-290.	2.0	12
603	Switch Rates During Acute Treatment for Bipolar II Depression With Lithium, Sertraline, or the Two Combined: A Randomized Double-Blind Comparison. American Journal of Psychiatry, 2017, 174, 266-276.	4.0	50
604	Treatment response in nonpsychotic vs psychotic manias – A follow up study from India. Asian Journal of Psychiatry, 2017, 26, 104-108.	0.9	4
605	Neuroprotection after a first episode of mania: a randomized controlled maintenance trial comparing the effects of lithium and quetiapine on grey and white matter volume. Translational Psychiatry, 2017, 7, e1011-e1011.	2.4	75
606	Do patients with bipolar disorder and subsyndromal symptoms benefit from functional remediation? A 12-month follow-up study. European Neuropsychopharmacology, 2017, 27, 350-359.	0.3	26

#	ARTICLE	IF	CITATIONS
607	Self-Reported Graphic Personal and Social Performance Scale (SRG-PSP) for measuring functionality in patients with bipolar disorder. Journal of Affective Disorders, 2017, 215, 256-262.	2.0	2
608	Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study. Lancet Psychiatry,the, 2017, 4, 208-217.	3.7	56
609	Quetiapine <i>v.</i> lithium in the maintenance phase following a first episode of mania: Randomised controlled trial. British Journal of Psychiatry, 2017, 210, 413-421.	1.7	53
610	Predictors of functional status at service entry and discharge among young people with first episode psychosis. Social Psychiatry and Psychiatric Epidemiology, 2017, 52, 575-585.	1.6	30
611	Bipolar mixed features – Results from the comparative effectiveness for bipolar disorder (Bipolar) Tj ETQq0 0	0 rgBT /Ον 2.0	erlock 10 Tf 5
612	American tertiary clinic-referred bipolar II disorder versus bipolar I disorder associated with hastened depressive recurrence. International Journal of Bipolar Disorders, 2017, 5, 2.	0.8	10
613	Eye movement desensitization and reprocessing therapy versus supportive therapy in affective relapse prevention in bipolar patients with a history of trauma: study protocol for a randomized controlled trial. Trials, 2017, 18, 160.	0.7	38
614	Abnormal sleep duration associated with hastened depressive recurrence in bipolar disorder. Journal of Affective Disorders, 2017, 218, 374-379.	2.0	22
615	Impact of irritability: a 2â€year observational study of outpatients with bipolar I or schizoaffective disorder. Bipolar Disorders, 2017, 19, 184-197.	1.1	18
616	Promoting medication adherence among patients with bipolar disorder: a multicenter randomized controlled trial of a multifaceted intervention. Psychological Medicine, 2017, 47, 2528-2539.	2.7	31
617	Rates and predictors of 18-months remission in an epidemiological cohort of 661 patients with first-episode psychosis. Social Psychiatry and Psychiatric Epidemiology, 2017, 52, 1089-1099.	1.6	23
618	A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use. Psychopharmacology, 2017, 234, 2233-2244.	1.5	12
619	Bipolar Disorder With Psychotic Features and Ocular Toxoplasmosis. Journal of Nervous and Mental Disease, 2017, 205, 192-195.	0.5	10
620	Social and academic premorbid adjustment domains predict different functional outcomes among youth with first episode mania. Journal of Affective Disorders, 2017, 219, 133-140.	2.0	9
621	Lifetime anxiety disorder and current anxiety symptoms associated with hastened depressive recurrence in bipolar disorder. Journal of Affective Disorders, 2017, 219, 165-171.	2.0	10
622	Early detection and integrated care for adolescents and young adults with psychotic disorders: the ACCESS III study. Acta Psychiatrica Scandinavica, 2017, 136, 188-200.	2.2	21
623	A randomized, doubleâ€blind, placebo―and risperidoneâ€controlled study on valnoctamide for acute mania. Bipolar Disorders, 2017, 19, 285-294.	1.1	6
624	Clinical correlates of acute bipolar depressive episode with psychosis. Journal of Affective Disorders, 2017, 217, 29-33.	2.0	19

#	Article	IF	CITATIONS
625	A novel approach to measuring response and remission in schizophrenia in clinical trials. Schizophrenia Research, 2017, 190, 123-128.	1.1	6
626	Organizational Learning Strategies and Verbal Memory Deficits in Bipolar Disorder. Journal of the International Neuropsychological Society, 2017, 23, 358-366.	1.2	9
627	Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2Âyears of treatment. International Journal of Bipolar Disorders, 2017, 5, 9.	0.8	20
628	Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectrums, 2017, 22, 333-341.	0.7	24
629	Methylene blue treatment for residual symptoms of bipolar disorder: Randomised crossover study. British Journal of Psychiatry, 2017, 210, 54-60.	1.7	44
630	Changes in white matter microstructure predict lithium response in adolescents with bipolar disorder. Bipolar Disorders, 2017, 19, 587-594.	1.1	58
631	Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Results from a pilot, randomized controlled trial. European Neuropsychopharmacology, 2017, 27, 959-969.	0.3	17
632	Trajectories of suicidal ideation over 6 months among 482 outpatients with bipolar disorder. Journal of Affective Disorders, 2017, 223, 146-152.	2.0	18
633	Aggressiveness in depression: a neglected symptom possibly associated with bipolarity and mixed features. Acta Psychiatrica Scandinavica, 2017, 136, 362-372.	2.2	31
634	An Open Trial of lloperidone for Mixed Episodes in Bipolar Disorder. Journal of Clinical Psychopharmacology, 2017, 37, 615-619.	0.7	6
635	Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis. International Journal of Clinical Practice, 2017, 71, e13037.	0.8	13
636	Use of Lithium in Severe Acute Manic Episodes: Retrospective Prescription Practice From a Tertiary Inpatient Unit. Journal of Psychiatric Practice, 2017, 23, 167-172.	0.3	0
637	Does the number of previous mood episodes moderate the relationship between alcohol use, smoking and mood in bipolar outpatients?. BMC Psychiatry, 2017, 17, 185.	1.1	4
638	L-Methylfolate For Bipolar I depressive episodes: An open trial proof-of-concept registry. Journal of Affective Disorders, 2017, 207, 429-433.	2.0	18
639	Illnesses in siblings of US patients with bipolar disorder relate to multigenerational family history and patients severity of illness. Journal of Affective Disorders, 2017, 207, 313-319.	2.0	1
640	Transdiagnostic Clinical Global Impression Scoring for Routine Clinical Settings. Behavioral Sciences (Basel, Switzerland), 2017, 7, 40.	1.0	42
641	Clinical correlates of loss of insight in bipolar depression. Trends in Psychiatry and Psychotherapy, 2017, 39, 264-269.	0.4	6
642	Switching bipolar disorder patients treated with clozapine to another antipsychotic medication: a mirror image study. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 201-204.	1.0	9

#	Article	IF	CITATIONS
643	Long-term response to mood stabilizer treatment and its clinical correlates in patients with bipolar disorders: a retrospective observational study. International Journal of Bipolar Disorders, 2017, 5, 24.	0.8	19
644	Lifetime eating disorder comorbidity associated with delayed depressive recovery in bipolar disorder. International Journal of Bipolar Disorders, 2017, 5, 25.	0.8	13
645	Anxiety, irritability, and agitation as indicators of bipolar mania with depressive symptoms: a post hoc analysis of two clinical trials. International Journal of Bipolar Disorders, 2017, 5, 36.	0.8	15
646	Cognitive functioning following stabilisation from first episode mania. International Journal of Bipolar Disorders, 2017, 5, 39.	0.8	3
647	Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder. Patient Preference and Adherence, 2017, Volume 11, 1019-1025.	0.8	11
648	An Assessment of Five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) commonly used Symptoms Rating Scales in Schizophrenia and Comparison to Newer Scales (CAINS, BNSS). Journal of Addiction Research & Therapy, 2017, 08, .	0.2	66
649	Differential effect of quetiapine and lithium on functional connectivity of the striatum in first episode mania. Translational Psychiatry, 2018, 8, 59.	2.4	59
650	Clinical and psychopathological features associated with treatment-emergent mania in bipolar-II depressed outpatients exposed to antidepressants. Journal of Affective Disorders, 2018, 234, 131-138.	2.0	16
651	Differential prevalence and demographic and clinical correlates of antidepressant use in American bipolar I versus bipolar II disorder patients. Journal of Affective Disorders, 2018, 234, 74-79.	2.0	3
652	Guselkumab, a human interleukinâ€23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52â€week, phase 3, multicenter, openâ€label study. Journal of Dermatology, 2018, 45, 529-539.	0.6	88
653	Longer-Term Effectiveness and Tolerability of Adjunctive Open Lurasidone in Patients With Bipolar Disorder. Journal of Clinical Psychopharmacology, 2018, 38, 207-211.	0.7	7
654	Associations of Comorbid Anxiety With Medication Adherence and Psychiatric Symptomatology in a Population of Nonadherent Bipolar Disorder Subjects. Journal of Nervous and Mental Disease, 2018, 206, 258-262.	0.5	1
655	Patterns and predictors of trajectories for social and occupational functioning in patients presenting with first-episode non-affective psychosis: A three-year follow-up study. Schizophrenia Research, 2018, 197, 131-137.	1.1	31
656	A pilot study of minocycline for the treatment of bipolar depression: Effects on cortical glutathione and oxidative stress in vivo. Journal of Affective Disorders, 2018, 230, 56-64.	2.0	36
657	Prevalence of axis <scp>II</scp> comorbidities in bipolar disorder: relationship to mood state. Bipolar Disorders, 2018, 20, 303-312.	1.1	18
658	The impact of affective temperaments on clinical and functional outcome of Bipolar I patients that initiated or changed pharmacological treatment for mania. Psychiatry Research, 2018, 261, 473-480.	1.7	16
659	A prospective observational study of problematic oral cannabinoid use. Psychopharmacology, 2018, 235, 409-417.	1.5	9
660	Episode accumulation associated with hastened recurrence and delayed recovery in bipolar disorder. Journal of Affective Disorders, 2018, 227, 657-664.	2.0	9

#	ARTICLE	IF	CITATIONS
661	Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency. Blood, 2018, 131, 1301-1310.	0.6	27
662	Treatment outcomes of acute bipolar depressive episode with psychosis. Depression and Anxiety, 2018, 35, 402-410.	2.0	9
663	Effects of adjunctive N-acetylcysteine on depressive symptoms: Modulation by baseline high-sensitivity C-reactive protein. Psychiatry Research, 2018, 263, 268-274.	1.7	27
664	Outcome and predictors of remission in bipolar-I patients experiencing manic episode and treated with oral antipsychotics and/or mood stabilizers. International Clinical Psychopharmacology, 2018, 33, 131-139.	0.9	6
665	Early detection and integrated care for adolescents and young adults with severe psychotic disorders: rationales and design of the Integrated Care in Early Psychosis Study ( <scp>ACCESS) Tj ETQq0 0 0 rg</scp>	;BT <b>ک9</b> erlo	ck <b>§</b> 0 Tf 50 5
666	sVCAM-1, sICAM-1, TNF-α and IL-6 levels in bipolar disorder type I: Acute, longitudinal and therapeutic implications. World Journal of Biological Psychiatry, 2018, 19, S41-S51.	1.3	21
667	Continuous circular cycling as a predictor of treatment response in bipolar disorders: a comprehensive review of the current literature. CNS Spectrums, 2018, 23, 24-28.	0.7	1
668	Modifiable and non-modifiable factors associated with functional impairment during the inter-episodic periods of bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 749-755.	1.8	24
669	Assessing bipolar disorder in the older adult: the GERIâ€BD toolbox. International Journal of Geriatric Psychiatry, 2018, 33, e150-e157.	1.3	3
670	Non-Suicidal Self-Injury in Pediatric Bipolar Disorder: Clinical Correlates and Impact on Psychosocial Treatment Outcomes. Journal of Abnormal Child Psychology, 2018, 46, 857-870.	3.5	16
671	Prefrontal activation during a working memory task differs between patients with unipolar and bipolar depression: A preliminary exploratory study. Journal of Affective Disorders, 2018, 225, 64-70.	2.0	61
672	Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder. Journal of Affective Disorders, 2018, 227, 649-656.	2.0	22
673	Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I Disorder. American Journal of Psychiatry, 2018, 175, 71-79.	4.0	51
674	Sleep disturbance may impact treatment outcome in bipolar disorder: A preliminary investigation in the context of a large comparative effectiveness trial. Journal of Affective Disorders, 2018, 225, 563-568.	2.0	18
675	Interactions Between Variation in Candidate Genes and Environmental Factors in the Etiology of Schizophrenia and Bipolar Disorder: a Systematic Review. Molecular Neurobiology, 2018, 55, 5075-5100.	1.9	117
676	A multi-centre, randomised, double-blind, placebo-controlled clinical trial of methylphenidate in the initial treatment of acute mania (MEMAP study). European Neuropsychopharmacology, 2018, 28, 185-194.	0.3	9
677	Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review. Paediatric Drugs, 2018, 20, 121-134.	1.3	9
678	Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder. Acta Neuropsychiatrica, 2018, 30, 297-305.	1.0	10

#	Article	IF	CITATIONS
679	Measurement tools for assessment of older age bipolar disorder: A systematic review of the recent global literature. Bipolar Disorders, 2018, 20, 359-369.	1.1	10
680	Associations between severity of anxiety and clinical and biological features of major affective disorders. Psychiatry Research, 2018, 260, 17-23.	1.7	14
681	Decreased activation and subsyndromal manic symptoms predict lower remission rates in bipolar depression. Australian and New Zealand Journal of Psychiatry, 2018, 52, 994-1002.	1.3	3
682	Comorbidity of chronic somatic diseases in patients with psychotic disorders and their influence on 4-year outcomes of integrated care treatment (ACCESS II study). Schizophrenia Research, 2018, 193, 377-383.	1.1	22
683	A Pilot Study of the Effectiveness of Lithium Versus Quetiapine Immediate Release Monotherapy in Patients With Bipolar Spectrum Disorders. Journal of Clinical Psychopharmacology, 2018, 38, 422-434.	0.7	16
684	Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study. International Journal of Bipolar Disorders, 2018, 6, 14.	0.8	15
685	Topical Analgesia with Lidocaine Plus Diclofenac Decreases Pain in Benign Anorectal Surgery: Randomized, Doubleblind, and Controlled Clinical Trial. Clinical and Translational Gastroenterology, 2018, 9, e210.	1.3	17
686	B-positive: a randomized controlled trial of a multicomponent positive psychology intervention for euthymic patients with bipolar disorder - study protocol and intervention development. BMC Psychiatry, 2018, 18, 335.	1.1	10
687	Cognitive and Functional Assessment of Psychosis Stratification Study (CoFAPSS): Rationale, Design, and Characteristics. Frontiers in Psychiatry, 2018, 9, 662.	1.3	2
688	The relationship between insight and affective temperament in bipolar disorder: an exploratory study. Trends in Psychiatry and Psychotherapy, 2018, 40, 210-215.	0.4	5
689	Symptom Dimensions and Trajectories of Functioning Among Bipolar Youth: A Cluster Analysis. Journal of Psychiatric Practice, 2018, 24, 146-157.	0.3	3
690	Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder. Bipolar Disorders, 2018, 21, 350-360.	1.1	5
691	Study Protocol for a Randomized Double Blind, Placebo Controlled Trial Exploring the Effectiveness of a Micronutrient Formula in Improving Symptoms of Anxiety and Depression. Medicines (Basel,) Tj ETQq0 0 0 r	gB <b>ō./</b> Overl	ock 10 Tf 50
692	Sweet Delight and Endless Night: A Qualitative Exploration of Ordinary and Extraordinary Religious and Spiritual Experiences in Bipolar Disorder. International Journal for the Psychology of Religion, The, 2018, 28, 31-54.	1.3	16
693	Axis II Personality Disorders Are Linked to an Adverse Course of Bipolar Disorder. Journal of Nervous and Mental Disease, 2018, 206, 469-472.	0.5	9
694	Interventions for the management of obesity in people with bipolar disorder. The Cochrane Library, 2018, , .	1.5	3
695	The user experiences and clinical outcomes of an online personal health record to support self-management of bipolar disorder: A pretest-posttest pilot study. Journal of Affective Disorders, 2018, 238, 261-268.	2.0	12
696	Cardiovascular risk and bipolar disorder: factors associated with a positive coronary calcium score in patients with bipolar disorder type 1. Revista Brasileira De Psiquiatria, 2018, 40, 163-168.	0.9	7

#	ARTICLE	IF	CITATIONS
697	Ruminative and dampening responses to positive affect in bipolar disorder and major depressive disorder. Comprehensive Psychiatry, 2018, 85, 72-77.	1.5	11
698	Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 1941-1952.	1.0	5
699	Changes in energy and motor activity: core symptoms of bipolar mania and depression?. Revista Brasileira De Psiquiatria, 2018, 40, 233-237.	0.9	10
700	Mindfulness-based social cognition training (SocialMIND) versus psychoeducational multicomponent intervention for people with a first episode of psychosis: a study protocol for a randomised controlled trial. BMC Psychiatry, 2019, 19, 233.	1.1	2
701	Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression. BMC Psychiatry, 2019, 19, 198.	1.1	6
702	Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. European Neuropsychopharmacology, 2019, 29, 971-985.	0.3	93
703	Emotional reactivity and neuropsychological assessment in ten cases of ablated temporal lobe tumors. Neurology Psychiatry and Brain Research, 2019, 34, 22-27.	2.0	0
704	Clinical applications of transcranial magnetic stimulation in bipolar disorder. Brain and Behavior, 2019, 9, e01419.	1.0	32
705	A randomized controlled trial comparing lithium plus valproic acid versus lithium plus carbamazepine in young patients with type 1 bipolar disorder: the LICAVAL study. Trials, 2019, 20, 608.	0.7	9
706	Bipolar depression and suicidal ideation: Moderators and mediators of a complex relationship. Journal of Affective Disorders, 2019, 259, 164-172.	2.0	13
707	Uncharted Waters: Treating Trauma Symptoms in the Context of Early Psychosis. Journal of Clinical Medicine, 2019, 8, 1456.	1.0	12
708	"The Awful Rowing toward Godâ€! Interpretation of Religious Experiences by Individuals with Bipolar Disorder. Pastoral Psychology, 2019, 68, 437-462.	0.4	9
709	Patterns of response to antidepressants in major depressive disorder: Drug resistance or worsening of depression are associated with a bipolar diathesis. European Neuropsychopharmacology, 2019, 29, 825-834.	0.3	41
710	Correlation between white blood cell count and mood-stabilising treatment response in two bipolar disorder trials. Acta Neuropsychiatrica, 2019, 31, 230-234.	1.0	2
711	An Observational Preliminary Study on the Safety of Long-Term Consumption of Micronutrients for the Treatment of Psychiatric Symptoms. Journal of Alternative and Complementary Medicine, 2019, 25, 613-622.	2.1	11
712	Neurophysiological effects of multiple mood episodes in bipolar disorder. Bipolar Disorders, 2019, 21, 503-513.	1.1	27
713	Adjunctive tianeptine treatment for bipolar disorder: A 24-week randomized, placebo-controlled, maintenance trial. Journal of Psychopharmacology, 2019, 33, 502-510.	2.0	12
714	Pilot study of a lifestyle intervention for bipolar disorder: Nutrition exercise wellness treatment (NEW Tx). Journal of Affective Disorders, 2019, 250, 278-283.	2.0	24

#	Article	IF	CITATIONS
715	The effect of adjunctive nutraceuticals in bipolar disorder: A systematic review of randomized placebo-controlled trials. Journal of Affective Disorders, 2019, 252, 334-349.	2.0	19
716	Clinical and Cognitive Correlates of Insight in Bipolar Disorder. Psychiatric Quarterly, 2019, 90, 385-394.	1.1	10
717	Predictive modeling for response to lithium and quetiapine in bipolar disorder. Bipolar Disorders, 2019, 21, 428-436.	1.1	15
718	Rates and predictors of one-year antipsychotic treatment discontinuation in first-episode schizophrenia: Results from an open-label, randomized, "real world―clinical trial. Psychiatry Research, 2019, 273, 631-640.	1.7	11
719	Antidepressants have complex associations with longitudinal depressive burden in bipolar disorder. Journal of Affective Disorders, 2019, 246, 836-842.	2.0	4
720	Improving functional outcomes in earlyâ€stage bipolar disorder: The protocol for the REsearch into COgnitive and behavioural VERsatility trial. Microbial Biotechnology, 2019, 13, 1470-1479.	0.9	10
721	Lower Switch Rate in Depressed Patients With Bipolar II Than Bipolar I Disorder Treated Adjunctively With Second-Generation Antidepressants. Focus (American Psychiatric Publishing), 2019, 17, 322-324.	0.4	1
722	Adaptation of the Clinical Global Impression for Use in Correctional Settings: The CGI-C. Frontiers in Psychiatry, 2019, 10, 687.	1.3	10
723	An adjunctive human-animal interaction intervention for veterans with PTSD: study protocol for a randomized controlled trial. Trials, 2019, 20, 786.	0.7	4
724	Efficacy and Safety of Asenapine Versus Olanzapine in Combination With Divalproex for Acute Mania. Journal of Clinical Psychopharmacology, 2019, 39, 305-311.	0.7	3
725	Prevalence of Religious and Spiritual Experiences and the Perceived Influence Thereof in Patients With Bipolar Disorder in a Dutch Specialist Outpatient Center. Journal of Nervous and Mental Disease, 2019, 207, 291-299.	0.5	13
726	Feasibility and Acceptability of a Lifestyle Intervention For Individuals With Bipolar Disorder. Journal of Psychiatric Practice, 2019, 25, 451-460.	0.3	6
727	Adaptive behavior in adolescents and adults with Down syndrome: Results from a 6â€month longitudinal study. American Journal of Medical Genetics, Part A, 2019, 179, 85-93.	0.7	5
728	Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale. Journal of Affective Disorders, 2019, 246, 126-131.	2.0	11
729	Risperidone adjunctive therapy duration in the maintenance treatment of bipolar I disorder: A post hoc analysis. Journal of Affective Disorders, 2019, 246, 861-866.	2.0	8
730	Sub-threshold bipolar disorder in medication-free young subjects with major depression: Clinical characteristics and antidepressant treatment response. Journal of Psychiatric Research, 2019, 110, 1-8.	1.5	14
731	Efficacy of adjunctive Garcinia mangostana Linn (mangosteen) pericarp for bipolar depression: study protocol for a proof-of-concept trial. Revista Brasileira De Psiquiatria, 2019, 41, 245-253.	0.9	8
732	Impaired glucose metabolism in bipolar patients and response to mood stabilizer treatments. Journal of Affective Disorders, 2019, 245, 174-179.	2.0	31

#	Article	IF	CITATIONS
733	Bumetanide for Autism Spectrum Disorder in Children: A Review of Randomized Controlled Trials. Annals of Pharmacotherapy, 2019, 53, 537-544.	0.9	24
734	Cognitive dysfunction in Malaysian patients with major depressive disorder: A subgroup analysis of a multicountry, crossâ€sectional study. Asia-Pacific Psychiatry, 2019, 11, e12346.	1.2	13
735	Effects of childhood trauma on adult moral decision-making: Clinical correlates and insights from bipolar disorder. Journal of Affective Disorders, 2019, 244, 180-186.	2.0	9
736	The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study. Journal of Affective Disorders, 2020, 266, 772-781.	2.0	13
737	Frailty, multimorbidity and functional status as predictors for health outcomes of acute psychiatric hospitalisation in older adults. Aging and Mental Health, 2020, 24, 119-128.	1.5	13
738	A Double-Blind Randomized Placebo-Controlled Trial of Citalopram Adjunctive to Stimulant Medication in Youth With Chronic Severe Irritability. Journal of the American Academy of Child and Adolescent Psychiatry, 2020, 59, 350-361.	0.3	49
739	Detailed assessment and risk factor analysis of corticosteroid-induced psychiatric disorders in pediatric, adolescent, and young adult patients undergoing induction or consolidation therapy for hematologic malignancy. Journal of Oncology Pharmacy Practice, 2020, 26, 1041-1051.	0.5	5
<b>7</b> 40	A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 83-94.	1.8	4
741	Diet quality, dietary inflammatory index and body mass index as predictors of response to adjunctive <i>N</i> -acetylcysteine and mitochondrial agents in adults with bipolar disorder: A sub-study of a randomised placebo-controlled trial. Australian and New Zealand Journal of Psychiatry, 2020, 54, 159-172.	1.3	11
742	Holy Apparition or Hyper-Religiosity: Prevalence of Explanatory Models for Religious and Spiritual Experiences in Patients with Bipolar Disorder and Their Associations with Religiousness. Pastoral Psychology, 2020, 69, 29-45.	0.4	10
743	Lithium vs valproate in the maintenance treatment of bipolar I disorder: A post- hoc analysis of a randomized double-blind placebo-controlled trial. Australian and New Zealand Journal of Psychiatry, 2020, 54, 298-307.	1.3	8
744	Clinical validation of the BDSx scale with bipolar disorder outpatients. Archives of Psychiatric Nursing, 2020, 34, 49-52.	0.7	9
745	Number of episodes in bipolar disorder: The case for more thoughtful conceptualization and measurement. Bipolar Disorders, 2020, 22, 231-244.	1.1	17
746	Physical Activity as a Predictor of Clinical Trial Outcomes in Bipolar Depression: A Subanalysis of a Mitochondrial-Enhancing Nutraceutical Randomized Controlled Trial. Canadian Journal of Psychiatry, 2020, 65, 306-318.	0.9	9
747	RadiocirugÃa estereotáctica con Gamma Knife® como tratamiento del temblor esencial y parkinsoniano: experiencia a largo plazo. NeurologÃa, 2023, 38, 188-196.	0.3	3
748	Relationship of comorbid personality disorders to prospective outcome in bipolar disorder. Journal of Affective Disorders, 2020, 276, 147-151.	2.0	8
749	Deconstructing major depressive episodes across unipolar and bipolar depression by severity and duration: a cross-diagnostic cluster analysis on a large, international, observational study. Translational Psychiatry, 2020, 10, 241.	2.4	9
750	Interventions for the management of obesity in people with bipolar disorder. The Cochrane Library, 2020, 2020, CD013006.	1.5	15

#	ARTICLE	IF	Citations
751	Investigation of the impact of an ADCY2 polymorphism as a predictive biomarker in bipolar disorder, suicide tendency and response to lithium carbonate therapy: the first report from Iran. Pharmacogenomics, 2020, 21, 1011-1020.	0.6	4
752	<scp>Doubleâ€blind</scp> , <scp>placeboâ€controlled</scp> study of lurasidone monotherapy for the treatment of bipolar I depression. Psychiatry and Clinical Neurosciences, 2020, 74, 635-644.	1.0	21
753	Community-Based Rehabilitation for Persons with Severe Mental Illness in a Rural Community of Karnataka: Methodology of a Randomized Controlled Study. Indian Journal of Psychological Medicine, 2020, 42, S73-S79.	0.6	8
754	Impact Evaluation of VKN–NIMHANS–ECHO Model of Capacity Building for Mental Health and Addiction: Methodology of Two Randomized Controlled Trials. Indian Journal of Psychological Medicine, 2020, 42, S80-S86.	0.6	10
755	Prevalence of Prediabetes and Diabetes Mellitus Type II in Bipolar Disorder. Frontiers in Psychiatry, 2020, 11, 314.	1.3	8
756	Toward prevention of bipolar disorder in at-risk children: Potential strategies ahead of the data. Journal of Affective Disorders, 2020, 272, 508-520.	2.0	18
757	The potential role of EMDR on trauma in affective disorders: A narrative review. Journal of Affective Disorders, 2020, 269, 1-11.	2.0	15
758	Magnetic seizure therapy for treatment-resistant depression. The Cochrane Library, 0, , .	1.5	0
759	An evaluation of suicidal risk in bipolar patients with comorbid posttraumatic stress disorder. Journal of Affective Disorders, 2020, 266, 49-56.	2.0	7
760	Is the 6â€item, selfâ€report HAMâ€D an effective depression screening measure with bipolar disorder?. Perspectives in Psychiatric Care, 2020, 56, 900-904.	0.9	8
761	Effects of psychotherapy on comorbid bipolar disorder and substance use disorder: A systematic review. Bipolar Disorders, 2021, 23, 141-151.	1.1	6
762	Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: Findings from the Bipolar CHOICE and LiTMUS trials. Depression and Anxiety, 2021, 38, 114-123.	2.0	5
763	A taxonomy of clinical response to mood stabilizers. Bipolar Disorders, 2021, 23, 24-32.	1.1	2
764	Does guideline-concordant care predict naturalistic outcomes in youth with early stage bipolar I disorder?. Journal of Affective Disorders, 2021, 278, 23-32.	2.0	2
765	The Koukopoulos mixed depression rating scale (KMDRS) and the assessment of mixed symptoms during the perinatal period. Journal of Affective Disorders, 2021, 281, 980-988.	2.0	5
766	Clinically meaningful changes on depressive symptom measures and patientâ€reported outcomes in patients with treatmentâ€resistant depression. Acta Psychiatrica Scandinavica, 2021, 143, 253-263.	2.2	23
767	The impact of BDNF variant on bipolar susceptibility, suicidal behavior, and response to lithium carbonate in bipolar patients. Meta Gene, 2021, 27, 100823.	0.3	0
768	Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study. Journal of Affective Disorders, 2021, 281, 160-167.	2.0	5

#	Article	IF	CITATIONS
769	Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder. Bipolar Disorders, 2021, 23, 595-603.	1.1	10
770	Case Report: Paliperidone Palmitate in the Management of Bipolar I Disorder With Non-compliance. Frontiers in Psychiatry, 2020, $11,529672$ .	1.3	1
771	The effect of N-acetylcysteine on bipolar depression: a systematic review and meta-analysis of randomized controlled trials. Psychopharmacology, 2021, 238, 1729-1736.	1.5	5
772	Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania. Journal of Psychopharmacology, 2021, 35, 971-982.	2.0	13
773	Psychotic symptoms during bipolar depressive episodes and suicidal ideation. Journal of Affective Disorders, 2021, 282, 1241-1246.	2.0	4
774	Influence of childhood trauma on the treatment outcomes of pharmacological and/or psychological interventions for adolescents and adults with bipolar disorder: protocol for a systematic review and meta-analysis. BMJ Open, 2021, 11, e044569.	0.8	1
775	Development of Evidence-Based Rehabilitation Practice in Botanical Garden for People With Mental Health Disorders. Herd, 2021, 14, 242-257.	0.9	5
776	Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression. Journal of the American Academy of Child and Adolescent Psychiatry, 2022, 61, 243-254.	0.3	12
777	Autobiographical Memory and Episodic Specificity Across Different Affective States in Bipolar Disorder. Frontiers in Psychiatry, 2021, 12, 641221.	1.3	4
778	Comorbidities, Depression Severity, and Circadian Rhythms Disturbances as Clinical Correlates of Duration of Untreated Illness in Affective Disorders. Medicina (Lithuania), 2021, 57, 459.	0.8	6
779	Electroconvulsive Therapy (ECT) in Bipolar Disorder Patients with Ultra-Rapid Cycling and Unstable Mixed States. Medicina (Lithuania), 2021, 57, 624.	0.8	4
780	Magnetic seizure therapy for treatment-resistant depression. The Cochrane Library, 2021, 2021, CD013528.	1.5	4
781	A Single-Blind Randomized Comparison of Lithium and Lamotrigine as Maintenance Treatments for Managing Bipolar II Disorder. Journal of Clinical Psychopharmacology, 2021, 41, 381-388.	0.7	6
782	Not in education, employment and training status in the early stages of bipolar I disorder with psychotic features. Microbial Biotechnology, 2021, , .	0.9	1
783	Use of Patient and Investigator Global Impression Scales: A Review of Food and Drug Administration–Approved Labeling, 2009 to 2019. Value in Health, 2021, 24, 1016-1023.	0.1	7
784	A Systematic Review of the Clinical Use of Gabapentin and Pregabalin in Bipolar Disorder. Pharmaceuticals, 2021, 14, 834.	1.7	6
785	Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52Âweek open label study. International Journal of Bipolar Disorders, 2021, 9, 25.	0.8	6
786	Illness stage and predominant polarity in bipolar disorder: Correlation with burden of illness and moderation of treatment outcome. Journal of Psychiatric Research, 2021, 140, 205-213.	1.5	5

#	Article	IF	CITATIONS
787	A protocol for the first episode psychosis outcome study ( <scp>FEPOS</scp> ): ≥15 year followâ€up after treatment at the <scp>Early Psychosis Prevention and Intervention Centre, Melbourne, Australia</scp> . Microbial Biotechnology, 2022, 16, 715-723.	0.9	3
788	The impact of lifetime interpersonal and intentional trauma on cognition and vulnerability to psychosis in bipolar disorder. BJPsych Open, 2021, 7, .	0.3	2
789	Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial. American Journal of Psychiatry, 2021, 178, 1098-1106.	4.0	46
790	Electroconvulsive Therapy for Bipolar Depression in Older Adults. Journal of ECT, 2021, 37, 182-188.	0.3	6
791	The effects of JNJ-39393406 a positive allosteric nicotine modulator on mood and cognition in patients with unipolar depression: A double-blind, add-on, placebo-controlled trial. European Neuropsychopharmacology, 2021, 51, 33-42.	0.3	9
792	Response and remission rates during 24 weeks of mood-stabilizing treatment for bipolar depression depending on early non-response. Psychiatry Research, 2021, 305, 114194.	1.7	1
793	Expanding bipolar outreach during college. Journal of Affective Disorders, 2021, 295, 28-32.	2.0	0
794	Massacre, Earthquake, Flood. International Perspectives in Psychology: Research, Practice, Consultation, 2021, 10, 39-54.	0.4	3
795	Asenapine: an atypical antipsychotic with atypical formulations. Therapeutic Advances in Psychopharmacology, 2021, 11, 204512532110352.	1.2	11
796	Substance Use Disorders and Associated Factors Among Adult Psychiatric Patients in Jimma Town, Southwest Ethiopia, 2017. Community-Based Cross-Sectional Study. Clinical Medicine Insights Psychiatry, 2021, 12, 117955732198969.	0.4	2
797	Development of an adapted Clinical Global Impression scale for use in Angelman syndrome. Journal of Neurodevelopmental Disorders, 2021, 13, 3.	1.5	12
798	Tiagabine in the treatment of acute affective episodes in bipolar disorder. , 2006, , CD004694.		<b>7</b> 5
799	Familial severe psychiatric history in bipolar disorder and correlation with disease severity and treatment response. Journal of Affective Disorders, 2020, 273, 131-137.	2.0	7
800	Demonstrating the impact of colocated behavioral health in pediatric primary care Clinical Practice in Pediatric Psychology, 2020, 8, 13-24.	0.2	3
801	The influence of current mood state, number of previous affective episodes and predominant polarity on insight in bipolar disorder. International Journal of Psychiatry in Clinical Practice, 2017, 21, 266-270.	1.2	4
802	Nimodipine Monotherapy and Carbamazepine Augmentation in Patients With Refractory Recurrent Affective Illness. Journal of Clinical Psychopharmacology, 1998, 18, 404-413.	0.7	86
803	Use of Atypical Antipsychotic Agents in Bipolar and Schizoaffective Disorders. Journal of Clinical Psychopharmacology, 1999, 19, 354-361.	0.7	40
804	A Placebo-Controlled Study of Lamotrigine and Gabapentin Monotherapy in Refractory Mood Disorders. Journal of Clinical Psychopharmacology, 2000, 20, 607-614.	0.7	385

#	Article	IF	CITATIONS
805	Models for the Quantitative Prediction of Therapeutic Responses Based on the Baseline EEG Parameters in Depressive Patients. Human Physiology, 2019, 45, 614-620.	0.1	3
806	Olanzapine Versus Placebo in the Treatment of Acute Mania. American Journal of Psychiatry, 1999, 156, 702-709.	4.0	456
807	Defining phenotypes of long-term lithium and valproate response, including combination therapy: a modified application of the Alda scale in patients with bipolar disorders. International Journal of Bipolar Disorders, 2020, 8, 36.	0.8	5
808	Predicting lithium treatment response in bipolar patients using gender-specific gene expression biomarkers and machine learning. F1000Research, 2018, 7, 474.	0.8	16
809	A double-blind comparison of the effect of the antipsychotics haloperidol and olanzapine on sleep in mania. Brazilian Journal of Medical and Biological Research, 2007, 40, 357-366.	0.7	20
810	The Portuguese version of the Clinical Global Impression - Schizophrenia Scale: validation study. Revista Brasileira De Psiquiatria, 2007, 29, 246-249.	0.9	38
811	Multidisciplinary clinical and psychological aspects of diagnosis. Autism and Developmental Disorders, 2016, 14, 51-67.	0.6	4
812	The use of atypical antipsychotics beyond psychoses: efficacy of quetiapine in bipolar disorder. Neuropsychiatric Disease and Treatment, 2006, 2, 139-148.	1.0	11
813	Can the response to mood stabilizers be predicted in bipolar disorder. Frontiers in Bioscience - Elite, 2014, E6, 120-138.	0.9	30
814	Cortical Volumetric Correlates of Childhood Trauma, Anxiety, and Impulsivity in Bipolar Disorder. Psychiatry Investigation, 2020, 17, 627-635.	0.7	9
815	Lamotrigine as an adjuvant treatment for acute bipolar depression: A Brazilian naturalistic study Psychology and Neuroscience, 2013, 6, 109-113.	0.5	3
816	Olanzapine for Psychotic Conditions in the Elderly. Psychiatric Annals, 2000, 30, 191-196.	0.1	35
817	Impact of Antidepressant Continuation After Acute Positive or Partial Treatment Response for Bipolar Depression. Journal of Clinical Psychiatry, 2009, 70, 450-457.	1.1	65
818	Olanzapine-Divalproex Combination Versus Divalproex Monotherapy in the Treatment of Bipolar Mixed Episodes. Journal of Clinical Psychiatry, 2009, 70, 1540-1547.	1.1	56
819	A Double-Blind, Placebo-Controlled Study of Quetiapine and Paroxetine as Monotherapy in Adults With Bipolar Depression (EMBOLDEN II). Journal of Clinical Psychiatry, 2010, 71, 163-174.	1.1	250
820	Improving Outcomes in Patients With Bipolar Depression. Journal of Clinical Psychiatry, 2015, 76, e10-e10.	1.1	10
821	Lurasidone in the Treatment of Bipolar Depression With Mixed (Subsyndromal Hypomanic) Features. Journal of Clinical Psychiatry, 2015, 76, 398-405.	1.1	57
822	Psychotherapy Alone and Combined With Medication as Treatments for Bipolar II Depression. Journal of Clinical Psychiatry, 2018, 79, 7-15.	1.1	31

#	Article	IF	CITATIONS
823	Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder. Journal of Clinical Psychiatry, 2017, 78, 324-331.	1.1	106
824	A 6-Month, Prospective, Randomized Controlled Trial of Customized Adherence Enhancement Versus Bipolar-Specific Educational Control in Poorly Adherent Individuals With Bipolar Disorder. Journal of Clinical Psychiatry, 2018, 79, .	1.1	14
825	Long-Term Olanzapine Therapy in the Treatment of Bipolar I Disorder. Journal of Clinical Psychiatry, 2001, 62, 273-281.	1.1	86
826	Factors Associated With Suicide Attempts in 648 Patients With Bipolar Disorder in the Stanley Foundation Bipolar Network. Journal of Clinical Psychiatry, 2003, 64, 506-515.	1.1	294
827	Safety of Available Agents Used to Treat Bipolar Disorder. Journal of Clinical Psychiatry, 2003, 64, 532-539.	1.1	75
828	A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Quetiapine or Lithium as Monotherapy for Mania in Bipolar Disorder. Journal of Clinical Psychiatry, 2005, 66, 111-121.	1.1	309
829	Preliminary Observations on the Effectiveness of Levetiracetam in the Open Adjunctive Treatment of Refractory Bipolar Disorder. Journal of Clinical Psychiatry, 2005, 66, 370-374.	1.1	53
830	Predictive Factors for Time to Remission and Recurrence in Patients Treated for Acute Mania. Primary Care Companion To the Journal of Clinical Psychiatry, 2008, 10, 114-119.	0.6	26
831	Efficacy and tolerability of injectable sodium valproate in patients with mania. Indian Journal of Psychiatry, 2006, 48, 118.	0.4	7
832	Caregiver Burden for Patients with Dementia with or Without Hiring Foreign Health Aides: A Cross-Sectional Study in a Northern Taiwan Memory Clinic. Journal of Medical Sciences (Taiwan), 2015, 35, 239.	0.1	29
833	Verbal and Visual Memory Impairments in Bipolar I and II Disorder. Psychiatry Investigation, 2012, 9, 339.	0.7	11
834	A Randomized Controlled Trial to Compare the Efficacy, Safety and Tolerability of Asenapine versus Olanzapine in Management of Schizophrenia. Clinical Psychopharmacology and Neuroscience, 2020, 18, 587-598.	0.9	1
835	What Is an Adequate Antipsychotic Trial? Using Plasma Levels to Optimize Psychiatric Response and Tolerability., 2021,, 114-146.		O
836	Suicidal Ideation in Bipolar Disorder: The Relation with Clinical and Sociodemographic Variables. Psychiatric Quarterly, 2022, 93, 453-461.	1.1	1
837	Dissociative Symptoms in Bipolar Disorder: Impact on Clinical Course and Treatment Response. Frontiers in Psychiatry, 2021, 12, 732843.	1.3	6
838	Deiodinase variation and liothyronine treatment interaction to accelerate ECT response in major depression: Pilot data and implications for thyroid pharmacogenomic testing in mood disorders. Personalized Medicine in Psychiatry, 2021, 29-30, 100089.	0.1	O
839	Tratamiento complementario del trastorno bipolar con gabapentina. European Psychiatry (Ed) Tj ETQq0 0 0 rgB	Γ/Overlock	R 10 Tf 50 102
840	Efectos a largo plazo del topiramato sobre la inestabilidad del estado de ánimo bipolar, el cambio de peso y el control glucémico: una serie clÃnica. European Psychiatry (Ed Española), 2001, 8, 361-365.	0.0	O

#	Article	IF	Citations
841	Classification of Bipolar Disordersâ€"Implications for Clinical Research. Medical Psychiatry, 2007, , 1-18.	0.2	0
842	Cognitive Behavioral Therapy for Older Adults with Bipolar Disorder. , 2008, , 249-263.		2
843	Global assessment scales. , 2010, , 3-7.		0
844	The Development of Questionnaire for Relapse Assessment in Psychotic Disorder. Journal of Korean Neuropsychiatric Association, 2013, 52, 417.	0.2	0
845	A comparison of a patient-rated visual analogue scale with the Liebowitz Social Anxiety Scale for social anxiety disorder: A cross-sectional study. Open Journal of Psychiatry, 2014, 04, 68-74.	0.2	2
846	A Prediction Model for Depression Risk. Ungyong T'onggye Yon'gu = the Korean Journal of Applied Statistics, 2014, 27, 317-330.	0.0	0
847	The effectiveness of a program of physical activity and diet to modify cardiovascular risk factors in patients with severe mental illness (CAPiCOR Study). International Archive of Medicine, 0, , .	1,2	0
848	Clinical and laboratory diagnosis of autism spectrum disorders in children. Laboratornaya Sluzhba, 2016, 5, 22.	0.0	8
849	Recognition and early aerobic exercise in prodrome of bipolar disorder: study protocol for a randomized controlled trial. Asia Pacific Journal of Clinical Trials Nervous System Diseases, 2017, 2, 9.	0.3	0
850	Deep-brain magnetic stimulation as add-on treatment to lithium carbonate in the treatment of bipolar depression: study protocol for a randomized, double-blind, sham-controlled trial. Asia Pacific Journal of Clinical Trials Nervous System Diseases, 2018, 3, 102.	0.3	0
851	Predicting lithium treatment response in bipolar patients using gender-specific gene expression biomarkers and machine learning. F1000Research, 2018, 7, 474.	0.8	8
853	Effect size of lithium, carbamazepine, and sodium valproate in child and adolescent bipolar 1 disorder during manic phase: A prospective open-label study. Industrial Psychiatry, 2019, 28, 185.	0.3	3
854	Mood versus energy/activity symptoms in bipolar disorder: which cluster of Hamilton Depression Rating Scale better distinguishes between mania, depression, and euthymia?. Trends in Psychiatry and Psychotherapy, 2019, 41, 401-408.	0.4	2
855	Is Low FODMAP Diet Effective in Children with Irritable Bowel Disease?. İstanbul Kuzey Klinikleri, 2020, 7, 433-437.	0.1	4
856	Care at door-steps for persons with severe mental disorders: A pilot experience from Karnataka district mental health program. International Journal of Social Psychiatry, 2022, 68, 273-280.	1.6	7
857	A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression. Journal of Affective Disorders, 2022, 296, 549-558.	2.0	10
858	Trends in (not) using scales in major depression: A categorization and clinical orientation. European Psychiatry, 2020, 63, e91.	0.1	8
859	The subjective concept of morbidity: its assessment and connection with the motivation for treatment in persons who underwent psychosis. V M Bekhterev Review of Psychiatry and Medical Psychology, 2020, , 73-79.	0.1	3

#	Article	IF	CITATIONS
862	Mood Disorders in Childhood. , 2008, , 143-160.		1
863	Carbamazepine extended-release capsules for the treatment of bipolar I disorder. Therapy: Open Access in Clinical Medicine, 2005, 2, 533-544.	0.2	0
864	Recovering the Capacity to Live outside of a Psychiatric Hospital: Impact of a Specialized Inpatient Program. Psychiatric Quarterly, 2021, 92, 751-759.	1.1	0
865	Effectiveness and weight effects of open-label lamotrigine with and without concomitant psychotropic medications in patients with bipolar I disorder. MedGenMed: Medscape General Medicine, 2007, 9, 41.	0.2	3
866	Safety of carbamazepine extended-release capsules used in combination with other psychotropic medications for the treatment of bipolar I disorder. Psychiatry, 2008, 5, 49-60.	0.3	1
867	The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry, 2007, 4, 28-37.	0.3	550
868	Use of a relapse monitoring board: an independent assessment for determining relapse in clinical trials for bipolar disorder. Innovations in Clinical Neuroscience, 2011, 8, 19-24.	0.1	36
869	Development and psychometric evaluation of a clinical global impression for schizoaffective disorder scale. Innovations in Clinical Neuroscience, 2012, 9, 15-24.	0.1	11
870	Efficacy and Safety of Once-versus Twice-Daily Carbamazepine Extended-Release Capsules for the Treatment of Manic Symptoms in Patients with Bipolar I Disorder. Psychiatry, 2008, 5, 35-48.	0.3	0
871	Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study. Psychopharmacology Bulletin, 2010, 43, 5-21.	0.0	10
872	Differential Anterior Cingulate Activity during Response Inhibition in Depressed Adolescents with Bipolar and Unipolar Major Depressive Disorder. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2014, 23, 10-9.	0.7	22
873	Lurasidone: a new treatment option for bipolar depression-a review. Innovations in Clinical Neuroscience, 2015, 12, 21-3.	0.1	7
874	Zonisamide for bipolar disorder, mania or mixed states: a randomized, double blind, placebo-controlled adjunctive trial. Psychopharmacology Bulletin, 2011, 44, 5-17.	0.0	15
875	Rating Scales and Safety Measurements in Bipolar Disorder and Schizophrenia Psychopharmacology Bulletin, 2017, 47, 77-109.	0.0	2
876	Asenapine in the Treatment of Bipolar Depression. Psychopharmacology Bulletin, 2020, 50, 8-18.	0.0	1
877	Smartphone Monitoring of Mood Instability in Young Depressed Patients: A Latent-class Analyses. AMIA Annual Symposium proceedings, 2019, 2019, 220-227.	0.2	0
878	Sequential Multiple Assignment Randomized Treatment (SMART) for Bipolar Disorder at Any Phase of Illness and at least Mild Symptom Severity. Psychopharmacology Bulletin, 2020, 50, 8-25.	0.0	2
879	The Role of Oxidative Stress in Suicidal Behaviour Among Bipolar Patients: A Cross-Sectional Study in a Malaysian Sample. Frontiers in Psychiatry, 2021, 12, 698911.	1.3	3

#	Article	IF	CITATIONS
880	Using the Clinical Global Impression scale to assess social communication change in minimally verbal children with autism spectrum disorder. Autism Research, 2022, 15, 284-295.	2.1	4
881	Cardiometabolic risk markers during mood-stabilizing treatment: Correlation with drug-specific effects, depressive symptoms and treatment response. Journal of Affective Disorders, 2022, 300, 41-49.	2.0	6
882	Oxcarbazepine versus sodium valproate in treatment of acute mania. International Clinical Psychopharmacology, 2022, Publish Ahead of Print, .	0.9	2
883	Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes. Australian and New Zealand Journal of Psychiatry, 2023, 57, 93-103.	1.3	3
884	Depressive and Anxious Temperaments as Predictors of Late Onset Bipolar Disorder? Preliminary Results of a "Real World―Exploratory Study. Frontiers in Psychiatry, 2022, 13, 836187.	1.3	1
885	Childhood trauma and treatment outcomes during moodâ€stabilising treatment with lithium or quetiapine among outpatients with bipolar disorder. Acta Psychiatrica Scandinavica, 2022, 145, 615-627.	2.2	9
886	Gamma Knife $\hat{A}^{\otimes}$ stereotactic radiosurgery as a treatment for essential and parkinsonian tremor: long-term experience. Neurolog $\tilde{A}$ a (English Edition), 2023, 38, 188-196.	0.2	3
887	Omega-3 fatty acids in bipolar patients with a low omega-3 index and reduced heart rate variability: the "BIPO-3―trial. International Journal of Bipolar Disorders, 2022, 10, 9.	0.8	1
888	Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. Lancet Psychiatry,the, 2022, 9, 291-306.	3.7	6
889	A customized adherence enhancement program for adolescents and young adults with suboptimal adherence and bipolar disorder: Trial design and methodological report. Contemporary Clinical Trials, 2022, 115, 106729.	0.8	6
890	Are personality disorders in bipolar patients more frequent in the US than Europe?. European Neuropsychopharmacology, 2022, 58, 47-54.	0.3	1
892	Levetiracetam adjunct to quetiapine for the acute manic phase of bipolar disorder: a randomized, double-blind and placebo-controlled clinical trial of efficacy, safety and tolerability. International Clinical Psychopharmacology, 2022, 37, 46-53.	0.9	4
895	Use of olanzapine for elderly patients with psychotic disorders: a review. Annals of Clinical Psychiatry, 2001, 13, 201-13.	0.6	8
896	Electroconvulsive Therapy for Unipolar Depression in Older Adults. Journal of ECT, 2022, Publish Ahead of Print, .	0.3	1
897	Association Between Lower Serum Free T <sub>4</sub> and Greater Mood Instability and Depression in Lithium-Maintained Bipolar Patients. American Journal of Psychiatry, 1999, 156, 1909-1914.	4.0	75
898	Protein Biomarkers in Monocytes and CD4 Lymphocytes for Predicting Lithium Treatment Response of Bipolar Disorder: a Feasibility Study with Tyramine-Based Signal-Amplified Flow Cytometry Psychopharmacology Bulletin, 2022, 52, 8-35.	0.0	1
899	Levels of circulating endothelial progenitor cells inversely correlate with manic and positive symptom severity in patients with bipolar disorder. Brain and Behavior, 2022, , e2570.	1.0	2
902	A systematic review and metaâ€analysis of treatments for rapid cycling bipolar disorder. Acta Psychiatrica Scandinavica, 2022, 146, 290-311.	2.2	18

#	Article	IF	Citations
903	Clinical and psychopathological correlates of duration of untreated illness (DUI) in affective spectrum disorders. European Neuropsychopharmacology, 2022, 61, 60-70.	0.3	7
905	Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia. Schizophrenia Bulletin, 2022, 48, 1273-1283.	2.3	5
906	Short-term aerobic exercise for depression in acute geriatric psychiatry: study protocol for a randomized controlled trial. Trials, 2022, 23, .	0.7	1
907	Internalized-stigma and dissociative experiences in bipolar disorder. Frontiers in Psychiatry, 0, 13, .	1.3	6
908	Efficacy and safety of daily home-based transcranial direct current stimulation as adjunct treatment for bipolar depressive episodes: Double-blind sham-controlled randomized clinical trial. Frontiers in Psychiatry, 0, 13, .	1.3	5
909	The Effect of Adjunctive Probiotics on Markers of Inflammation and Oxidative Stress in Bipolar Disorder: A Double-blind, Randomized, Controlled Trial. Journal of Psychiatric Practice, 2022, 28, 373-382.	0.3	3
910	Cutoff for Benchmark Disability Using World Health Organization Disability Assessment Schedule 2.0: A Community-Based Cross-Sectional Study from Rural South India. Indian Journal of Psychological Medicine, 0, , 025371762211241.	0.6	0
911	Cognitive profiles in bipolar I disorder and associated risk factors: Using Wechsler adult intelligence scale—IV. Frontiers in Psychology, 0, 13, .	1.1	O
912	Protocol for a randomised placebo-controlled trial investigating the efficacy and safety of a vitamin-mineral formula targeting dysregulated emotions in teenagers: The balancing emotions of adolescents with micronutrients (BEAM) study. Contemporary Clinical Trials Communications, 2022, 30, 101027.	0.5	0
913	Mediators of quality of life change in people with severe psychotic disorders treated in integrated care (ACCESS II study). European Psychiatry, 0, , 1-24.	0.1	1
915	Premorbid features of youth depression patients with attenuated schizophrenic symptoms. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2022, 122, 110.	0.1	0
916	Impact of incentivizing ASHAs on the outcome of persons with severe mental illness in a rural South Indian community amidst the COVID-19 pandemic. Asian Journal of Psychiatry, 2023, 80, 103388.	0.9	2
917	Increased cortical surface area but not altered cortical thickness or gyrification in bipolar disorder following stabilisation from a first episode of mania. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2023, 122, 110687.	2.5	1
919	Group psychoeducation for persons with bipolar disorder in Rwanda: a study protocol for a randomized controlled trial. Trials, 2022, 23, .	0.7	2
920	Circulating endothelial progenitor cell dysfunction in patients with bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience, 0, , .	1.8	1
921	Divergent Directionality of Immune Cell-Specific Protein Expression between Bipolar Lithium Responders and Non-Responders Revealed by Enhanced Flow Cytometry. Medicina (Lithuania), 2023, 59, 120.	0.8	2
922	The efficacy of lumateperone on symptoms of depression in bipolar I and bipolar II disorder: Secondary and post hoc analyses. European Neuropsychopharmacology, 2023, 68, 78-88.	0.3	4
923	Pharmacological Treatment of Bipolar Depression: A Review of Observational Studies. Pharmaceuticals, 2023, 16, 182.	1.7	0

#	Article	IF	CITATIONS
925	Adjunctive lumateperone ( <scp>ITI</scp> â€007) in the treatment of bipolar depression: Results from a randomized <scp>placeboâ€controlled</scp> clinical trial. Bipolar Disorders, 2023, 25, 478-488.	1.1	6
926	Differences in intracellular protein levels in monocytes and CD4+ lymphocytes between bipolar depressed patients and healthy controls: A pilot study with tyramine-based signal-amplified flow cytometry. Journal of Affective Disorders, 2023, 328, 116-127.	2.0	0
927	A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder. CNS Drugs, 2023, 37, 337-350.	2.7	6